OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
1   
TITLE:   A Dose Escalation  Study of Selinexor (KPT -330), a Selective Inhibitor of Nuclear 
Export, and Ibrutinib, a Bruton’s Tyrosine Kinase Inhibitor, in Patients with Relapsed and 
Refractory Chronic Lymphocytic Leukemia or Aggressive Non- Hodgkin Lymphoma  
  Principal Investigator:  Jennifer A Woyach, MD 
 455A Wiseman Hall  
 410 W 12
th Ave   
 Columbus, Ohio 43210 
 (614) 685-5667 
 Jennifer.woyach@osumc.edu 
  
 Laboratory Co-Investigators:  Mitch Phelps, PhD 
 Rosa Lapalombella, PhD 
 Larry Schaaf, PhD 
 Statistician: Amy S. Ruppert , MAS  
 Multi -Center Trial Program  
Clinical Trials Office  
The Ohio State University Comprehensive Cancer Center Fax: 614-366-6652 E: OSUCCC -CTO -MCTP@osumc.edu  
 Initial Protocol  14 Nov 2014 
Amendment 1  25 Jan 2016 
Amendment 2  03 May 2016 
Amendment 3  10 Jan 2017 
Amendment 4  03 Oct 2017 
Amendment 5 12 Jun 2018 Amendment 6  07 April 2020 
Amendment 7         03 August 2021 
   
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
2    
Investigational Agent  IND#  IND Sponsor  
Selinexor (KPT -330) 124150  The Ohio State University  
 Study Cohorts:  
         SCHEMA 
Eligibility Criteria* Required Initial 
Laboratory Values  
1.Histologically confirmed chronic lymphocytic leukemia , small 
lymphocytic leukemia, B- cell prolymphocytic leukemia, or 
variants of this or B -cell non -Hodgkin’s lymphoma (NHL) of any 
of the following subtypes recognized by the WHO classification: mantle cell lymphoma, diffuse large B -cell lymphoma  not 
otherwise specified , or transformed lymphoma. 
2.At least one prior therapy 3.ECOG performance status 0 -1 
4.Age ≥ 18 years  
5.Patients are excluded who : 
• Have received chemotherapy or radiotherapy ≤  4 weeks, 
nitrosoureas or mitomycin C ≤ 6 weeks, or immunotherapy/ targeted agents (such as kinase inhibitors) ≤ 2 weeks  (except 
patients already on ibrutinib). 
• Require anticoagul ation with warfarin . 
• Require therapy with strong inducers or inh ibitors of CYP3A4/5 . ANC# ≥ 1,000/mm3 
Platelets$ ≥ 50,000/mm3 
Creatinine  clearance ≥ 
30ml/min  
Total bilirubin^ ≤ 2.0 x 
ULN  
AST/ALT# < 2.5 ULN 
   
 
*Please refer to Section 3 for the complete eligibility cri teria. #Unless these v alues are secondary to bone marrow 
involvement of CLL/NHL.  $Platelets ≥ 30,000/mm3 in the setting of bone marrow involvement.  ^Unless due to Gilberts.  
 
Regimen Description  
Agent  Precautions  Dose  Route  Schedule  Cycle Length  
Ibrutinib  Take with 8 oz  of water, 
30 min before meal Capsule  
or 
tablet* Oral Cycle 1 Days 8-
28**, Cycles 2+ 
Days 1 -28 28 days (4 
weeks)  
Selinexor  Take with at least 120 
mL (4 ounces) of fluids 
(water, juice, etc.)  Tablet* Oral Days 1,8, and 15 of 
each cycle* 
*Doses /schedule  as appropriate for assigned dose level.  Cohort 1: 
Selinexor Dose 
Escalation  Cohort 2: 
Selinexor + 
Ibrutinib 
Expansion Cohort
  Cohort 3: 
Selinexor added 
to frontline 
Ibrutinib in CLL 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
3 **Patients continuing on ibrutinib should take ibrutinib days 1 -28 of Cycle 1  
 
 
Dose 
Level  Selinexor 
Dose  Selinexor 
Schedule  Ibrutinib 
Dose   Ibrutinib 
Schedule  
1* 40 mg  Weekly (oral)  420 mg Daily (oral)  
2 20 mg  Bi-weekly (oral)  420 mg Daily (oral)  
   For the phase I study, a n adaptive dose finding design using a modified continuous reassessment 
method will be followed . Once the MTD of selinexor in combination with ibrutinib is identified , 
an expansion cohort of up to 10 CLL patients and 10 lymphoma pat ients will be accrued to better 
describe the toxicity profile, evaluate feasibility of pharmacodynamics studies, and to gain additional efficacy data.  Dose -limiting toxicity (DLT) will b e assessed during cycle 1 only.  
Provided the patient does not experie nce significant toxicity, patients may continue treatment 
until disease progression. Respons e will be assessed by PET/CT, CT , and/or peripheral blood 
immunophenotyping every 3 cycles during the 1st year of therapy and then every 6 months until disease prog ression or as medically indicated.  PET/CT is preferred in lymphoma patients.  In 
patients with bone marrow involvement at the start of therapy, a bone marrow biopsy will be performed to confirm a complete response (CR).  Additionally, bone marrow biopsy w ill be 
performed at 1 year and then yearly provided other criteria for CR exist.   
Definition of DLT for patients receiving selinexor and ibrutinib* 
General  
• Treatment delays > 28 days for any toxicity  
• Any grade 5 toxicity  
Non-hematologic  
• Grade 3 nausea/vomiting or diarrhea lasting for ≥7 days while taking optimal 
supportive medications# 
• Grade 3 anorexia or fatigue lasting for ≥7 days while taking optimal supportive care# and with correction of dehydration, anemia, endocrine, or electrolyte abnormalities  
• Grade ≥ 3 AST or ALT elevation lasting for ≥7 days OR any Grade ≥ 3 AST or ALT elevation in the setting of bilirubin elevation > 2x ULN Any other Grade 3 non-hematological toxicity except alopecia, rash that resolves to Grade 1 in  ≤ 7 days, or electrolytes abnormalities correctable with supportive therapy#  
• Any Grade 4 non -hematologic toxicity not specifically listed above  
Hematologic  
• Grade 4 neutropenia [absolute neutrophil count  (ANC) < 500/mm3] lasting ≥7 days$; 
• Grade 4 t hrombocytopenia (platelet count <25,000/mm3) that persists for ≥7 days$; 
• Grade ≥ 3 t hrombocytopenia- associated bleeding; or  
• Grade 4 febrile neutropenia (ANC < 1000/mm3 with a single temperature ≥ 38.3ºC or 
sustained temperature of >38°C for over 1 hour).  
*Assessed during Cycle 1 by CTCAEv4 criteria #Section 4.4 provides detailed supportive care  $Only for patients 
with normal cell counts at study start  (See Section 4.2)  ^For patients with Gilbert’s syndrome: >2X baseline  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
4 TABLE OF CONTENTS  
 
1.
 OBJECTIVES  ......................................................................................................................7  
1.1 Primary Objectives ...................................................................................................7  
1.2 Secondary Objectives ...............................................................................................7  
1.3 Exploratory Correlative and Pharmacodynamic Objectives ....................................7  
2. BACKGROUND  .................................................................................................................7  
2.1 Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma .........................7  
2.2 B-cell Receptor Pathway in Lymphoid Malignancies .............................................8  
2.3 Ibrutinib in Chronic Lymphocytic Leukemia ..........................................................8  
2.4 Ibrutinib in Mantle Cell Lymphoma  ........................................................................9  
2.5 Ibrutinib in Diffuse Large B-cell Lymphoma ........................................................10  
2.6 Tumor Suppressor Protein (TSP) and Growth Regulatory Protein (GRP) 
Nuclear Export  .......................................................................................................11  
2.7 Inhibition of XPO1 in Human Cancer ...................................................................12  
2.8 Selective Inhibitors of Nuclear Export (SINE) ......................................................12  
2.9 Selinexor Preclinical and Clinical Data  .................................................................13  
2.10  Rationale for the Study ..........................................................................................15  
2.11  Rationale for the Dose/Dosing Schedule  ...............................................................15  
2.12  Correlative Studies Background ............................................................................16  
3. PATIENT SELECTION  ....................................................................................................17  
3.1 Eligibility Criteria  ..................................................................................................17  
3.2 Exclusion Criteria  ..................................................................................................19  
3.3 Inclusion of Women and Minorities ......................................................................21  
4. REGISTRATION PROCEDURES  ...................................................................................21  
5. TREATMENT  ...................................................................................................................22  
5.1 Overview  ................................................................................................................22  
5.2 Agent Admini stration .............................................................................................23  
5.3 Definition of Dose Limiting Toxicity  ....................................................................26  
5.4 Concomitant Medications ......................................................................................27  
5.5 Prevention of Pregnancy ........................................................................................27  
5.6 Blood Products .......................................................................................................27  
5.7 Radiation Treatment ...............................................................................................27  
5.8 Glucocorticoid Therapy .........................................................................................28  
5.9 Anti-diarrheal Medications  ....................................................................................28  
5.10  General Medications  ..............................................................................................28  
5.11  Procedures  ..............................................................................................................28  
5.12  Anticancer Therapy  ................................................................................................28  
5.13  Investigational Agents ...........................................................................................28  
5.14  Drugs undergoing Glutathione conjugation ...........................................................29  
5.15  Drugs that inhibit or induce CYP 3A4/5................................................................29  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
5 5.16
 Warfarin  .................................................................................................................29  
5.17  Concomitant Treatments for Selinexor ..................................................................29  
5.18  Supportive Care Guidelines for selinexor ..............................................................30  
Table:  Supportive Care and Selinexor Dose Adjustment Guidelines for AEs related to 
Selinexora,b .........................................................................................................................30  
1. aFor all  Grade ≥3  hematologic  or non-hematologic AEs that  are NOT  selinexor related, 
after consultation with the Medical Monitor and at the discretion of the Investigator, selinexor dosing may be maintained. .................................................................................33
 
2. bFor all selinexor- related AE’s, if the below prescribed dose reductions/interruptions 
result in a stabilization of ≥ 4 weeks, a re- escalation may be considered after approval 
from the Medical Monitor.  .................................................................................................33  
3. All dose modifications should be based on the worst preceding toxicity. .........................33  
4. Note: When toxicities due to selinexor have returned to baseline levels or the patient has stabilized, the dose of selinexor may be re- escalated in consultation with the Medical 
Monitor. .............................................................................................................................33
 
5.19  Duration of Therapy ...............................................................................................33  
5.20  Duration of Follow Up ...........................................................................................34  
5.21  Criteria for Removal from Treatment  ....................................................................34  
6. DOSING DELAYS/DOSE MODIFICATIONS  ...............................................................34  
6.1 Dose adjustment guidelines for hematologic ibrutinib or selinexor- related 
toxicities  .................................................................................................................35  
6.2 Dose adjustment guidelines for non-hematologic ibrutinib or selinexor-related toxicities  .....................................................................................................37
 
6.3 Dose Reduction for Decreased Glomerular Filtration Rate (GFR)  .......................44  
6.4 Dose Adjustment for Infection  ...............................................................................44  
6.5 Conditions not Requiring Dose Reduction ............................................................45  
6.6 Missed or Vomited Doses ......................................................................................45  
6.7 Delays, Modifications and Reintroduc tion ............................................................45  
7. ADVERSE EVENTS (AEs):  LIST AND REPORTING REQUIREMENTS  ..................45  
7.1 Definition of an Adverse Event .............................................................................46  
7.2 Recording of Adverse Events ................................................................................46  
7.3 Laboratory Test Abnormalities ..............................................................................46  
7.4 Adverse Events of Special Interest  ........................................................................47  
7.5 Adverse Event Severity Assessments  ....................................................................47  
7.6 Adverse Event Causality  ........................................................................................48  
7.7 Adverse Event Reporting .......................................................................................48  
7.8 Serious Adverse Events .........................................................................................48  
7.9 Recording of Serious Adverse Events ...................................................................49  
7.10  Reporting of Serious Adverse Events ....................................................................49  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
6 7.11
 Suspected Unexpected Serious Adverse Reactions  ...............................................50  
7.12  Procedures for Handling Special Situations ..........................................................50  
7.13  Abuse, Misuse, Medication Errors, Overdose, and Occupational Exposure .........51  
7.14  Data Safety Monitoring Plan .................................................................................52  
8. PHARMACEUTICAL INFORMATION  ..........................................................................52  
8.1 Selinexor Description/Availability  ........................................................................52  
8.2 Ibrutinib Description/Availability  ..........................................................................55  
9. CORRELATIVE STUDIES  ..............................................................................................56  
9.1 Ibrutinib Steady State Plasma Levels  ....................................................................56  
9.2 Pharmacodynamic (PD) properties of Selinexor ...................................................57  
9.3 Pharmacogenomics (PGx)  .....................................................................................58  
9.4 Primary and Secondary Resistance Studies ...........................................................58  
10. STUDY CALENDAR  .......................................................................................................60  
11. MEASUR EMENT OF EFFECT ..........................................................................................0  
11.1  Response Criteria  .....................................................................................................0  
12. DATA REPORTING / REGULATORY REQUIREMENTS  .............................................4  
12.1  Patient Protection  .....................................................................................................4  
12.2  Patient Information  ..................................................................................................4  
12.3  Informed Consent.....................................................................................................5  
12.4  Data Submission  ......................................................................................................5  
13. STATISTICAL CONSIDERATIONS .................................................................................5  
13.1  Study Design ............................................................................................................5  
13.2  Sample Size/Accrual Rate ........................................................................................5  
13.3  Evaluability  ..............................................................................................................6  
13.4  Definition of Primary Endpoint ...............................................................................6  
13.5  Definition of Secondary Endpoints ..........................................................................6  
13.6  Definition of Exploratory Endpoints .......................................................................7  
13.7  Analytic Plan for Primary Objective ........................................................................7  
13.8  Analytic Plan for Secondary Objectives  ..................................................................9  
APPENDIX A  PERFORMANCE STATUS CRITERIA  ..................................................14  
APPENDIX B  INDUCERS AND INHIBITORS CYP3A4/5  ...........................................15  
APPENDIX C  STAGING SYSTEMS  ...............................................................................16  
Appendix D Karyopharm SAE Report form .................................................................................17  
   
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
7 1. OBJECTIVES  
 1.1 Primary Objectives  
 To determine the maximum tolerated dose for the combination of selinexor and ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia(SLL)/ B-cell prolymphocytic leukemia (PLL) or aggressive non-Hodgkin lymphoma 
(NHL).  
 1.2 Secondary Objectives  
 
1.2.1 To characterize the safety and tolerability of the combination of selinexor and ibrutinib in patients with relapsed or refractor y CLL/SLL/PLL or a ggressive NHL. 
1.2.2 To obtain preliminary data on efficacy of the combination of selinexor and ibrutinib in patients with relapsed or refractory CLL/SLL/PLL or aggressive NHL. 
1.2.3 To obtain preliminary data on response in CLL/SLL/PLL and diffuse large B -cell 
lymphoma (DLBCL) patients receiving the combination of selinexor and ibrutinib as related to CLL/SLL/PLL karyotype and IgVH mutational status and DLBCL subtype, respectively.  
1.2.4 To obtain preliminary data on the ability of selinexor to improve response depth with ibrutinib when given to patients receiving initial therapy (Cohort 3) 
 1.3 Exploratory Correlative and Pharmacodynamic Objectives 
1.3.1 To evaluate the inhibition of the B-cell receptor signaling pathway in patients with relapsed or refractory CLL/SLL/PLL who receive the combination of selinexor and ibrutinib. 
1.3.2 To characterize the pharmacokinetic (PK) properties of the combination of selinexor and ibrutinib in patients with relapsed or refractory CLL/SLL/PLL or aggressive NHL.   
 
1.3.3 To evaluate the change in localization of tumor suppressor and growth regulation proteins in patients with relapsed or refractory CLL/SLL/PLL following treatment with selinexor in general and as related to response.  
1.3.4 To preliminarily assess potential causes for primary and secondary resistance to selinexor and ibrutinib. 
1.3.5 To measure intracellul ar levels of selinexor and metabolites in peripheral blood 
mononuclear cells and to identify how this relates to pharmacodynamics effects and clinical outcomes.  
 2. BACKGROUND 
 2.1 Chronic Lymphocytic Leukemia and Non -Hodgkin’s Lymphoma    
 
Chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), including mantle cell lymphoma (MCL) and diffus e large B -cell lymphoma (DLBCL) are the most common types of 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
8 adult hematologic malignancies in the United States
1.  In 2012, the estimated number of new 
cases of CLL and NHL were 16,060 and 70,130, respectively1.  The same year, 4,580 and 18,940 
people were projected to die as a cause of CLL or NHL, respectively1.  Over the years, 
significant advances in the treatment of these cancers were achieved and the therapy evolved from standard chemotherapy agents to chemotherapy agents in combination with immunotherapeutic compounds such as monoclonal antibodies.   However, despite this progress, there is currently no cure for relapsed or refractory CLL or NHL outside of aggressive therapy with hematopoietic stem cell transplantation.  Therefore, there has been much interest in developing novel therap eutic options for this group of patients.  Of late, targeted agents have 
shown great promise in CLL and NHL therapy with a focus on the B- cell receptor pathway.       
 2.2 B-cell Receptor Pathway in Lymphoid Malignancies  
 Chronic activation of the B-cell receptor pathway has been shown to play a crucial  role in the 
survival of CLL
2, MCL3, and DLBCL cells4.  Therefore, inhibition of the components of the B-
cell receptor pathway has become an attractive therapeutic target in the treatment of these malignancies.  A critical component of this pathway is Bruton’s agammaglobulinemia tyrosine kinase (BTK), a non-receptor tyrosine kinase in the Tec kinase family, which is expressed predominantly in B-lymphocytes but not in T- or NK -cells and is also down- regulated in plasma 
cells
5.  BTK is critical for B -cell development, differentiation, signaling, proliferation, and 
survival5.  Mutation of the BTK gene leads to X-linked agammaglobulinemia in humans, which 
results in lack of circulating B -cells, inability to produce immunoglobulins and significant 
susceptibility to infection6.  Functional BTK is essential for activation of several survival 
pathways including the Akt, extracellular signal –regulated kinase (ERK),  and nuc lear factor 
kappa light- chain enhancer of activated B cells (NF -κB) pathways7.  Ibrutinib is an orally 
bioavailable, potent, irreversible inhibitor which covalently binds to the cysteine-481 amino acid of the BTK enzyme
8.  Over the past few years, research using ibrutinib to target multiple B- cell 
malignancies has been wildly successful.  2.3 Ibrutinib in Chronic Lymphocytic Leukemia  
 There is significant evidence to suggest that the viability of CLL cells is dependent on B- cell 
receptor signaling.  Unmutated status of the immunoglobulin variable heavy chain (IgVH) is one of the strongest predictive factors for poor prognosis in CLL patients
9, 10.  This finding has been 
attributed to enhanced signaling and dependence on the B- cell receptor pathway in this patient 
subset.  ZAP70 and CD38 are additional molecules that modify B-cell receptor signaling and are associated with poor prognosis in CLL patients
10, 11.  These prognostic observations gave strong 
rationale to use B -cell receptor pathway inhibitors, such as ibrutinib, in CLL patients. 
 Preclinical studies  with ibrutinib  in CLL cells and models have demonstrated multiple cellular 
effects , including abrogation of the ER K, phosphatidylinositide 3-kinase (PI3K), and NF -κB 
survival pathways.  Ibrutinib inhibited activation-induced proliferation of CLL cells and blocked survival signals to CLL cells from the microenvironment, including soluble factors (CD40L, BAF F, IL -6, IL -4, and TNF- α), fibronectin engagement, and stromal cell contact .  Importantly, 
ibrutinib did not interfere with T- cell survival
12.   
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
9  Due to this research and other strong preclinical data, ibrutinib ente red clinical trials in patients 
with relapsed and refractory CLL.   Sixteen of the 56 patients with B- cell malignancies in an 
early phase I trial of ibrutinib
13 were patients with CLL.  Eleven of these 16 patients experienced 
rapid reduction of lymphadenopathy during cycle one of treatment, which was accompanied by an increase in peripheral lymphocytosis suggesting a redistribution of CLL cells from the lymph nodes into the peripheral blood.  Ibrutinib was generally we ll-tolerated and o f all toxicities, the 
most common adverse events were typically grade 1 or 2, including diarrhea (42.9%), nausea (41.1%), fatigue (37.5%), myalgia (37.5%), and dyspepsia (30.4%)
13.  This trial led to a 
landmark phase Ib/II study in 85 relapsed and refractory CLL patients8 where patients were 
assigned to receive either 420mg (n=51) or 840mg (n=34) of oral ibrutinib daily until disease progression or intolerable adverse events.  The overall response rate (ORR)  was 71% in both 
dose cohorts when based on standard response criteria
14.  An additional 20% and 15% of patients 
in the 420mg and 840mg cohorts, respectively, achieved a pa rtial response with residual 
lymphocytosis8.  Prolonged lymphocytosis during ibrutinib therapy has subsequently been found 
not to indicate a suboptimal response to therapy15.  Response rates were not different between 
several known high-risk populations, with the exception of a worse response seen in patients with mutated -IgVH.  Correlative analyses demonstrated a greater than 90% occupancy of the 
pharmacodynamics BTK probe and similar response rates between the groups that received 420 mg and 840 mg, which provided support for the use of the 420 mg dose in CLL patients.  Again, ibrutinib was well-tolerated and the most common adverse events were grade 1 or 2 and included 
diarrhea (47%), and upper respiratory tract infection  (33%), fatigue (28%), and most adverse 
events resolved  without holding therapy.  The 26- month estimated rate s of progression- free 
survival (PFS) and overall survival (OS) were 75% and 83%, respectively.  Th is study led to the 
ultimate approval of ibrutinib for relapsed/refractory CLL patients by the US Food and Drug Administration (FDA).  Although these results are very promising, there remains a subset of high 
risk, most notably patients with del(17p13.1) karyotype, who demonstrated a shorter PFS and OS of 57% and 70%, respectively
8.   
 This finding indicates that there is a subset of patients that will become resistant to therapy with ibrutinib and will need alternative  therapeutic options.  Six CLL patients who relapsed while 
treated with single -agent ibrutinib on clinical trial were analyzed to detect mechanisms of 
resistance. Whole exome sequencing  was performed at baseline and relapse on samples from 
these patients.  In 5 of the patients, a cysteine- to-serine substitution at position of 481 of BTK 
(C481S; binding site of ibrutinib) was identified.  In 2 patients, three distinct gain of function mutations were identified in  PLC ᵧ2 (S707Y, R665W, and L845F), which lead to autonomous B-
cell receptor signaling pathway.  Both types of mutations indicate an acquired resistance to ibrutinib and further emphasize the need for alternate or combination therapies for these patients.  Although only a small portion of patients have developed acquired resistance to ibrutinib, the study of the 6 patients suggest that patients with more genomic instability, including those with del(17p13.1), del(11q22.3), and complex karyotype may be at particular risk for relapse on ibrutinib
16 (unpublished data Byrd laboratory).   
 2.4 Ibrutinib in Mantle Cell Lymphoma  
 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
10 Preclinical data has also pointed to the importance of B -cell receptor signaling in MCL.  
Although IgVH stereotypes discovered in MCL were distinct from those in CLL, highly restricted immunoglobulin genes are thought to imply a role for antigen-driven selection of the clonogenic progenitors
17.  When constitutively activated, signal transducer and activator of 
transcription 3 (STAT3), promotes cell growth and survival through dysregulated protein expression and contributes to the malignant phenotype in numerous cancer types
18.  STAT3 was 
found to be activated in pri mary MCL cells in response to B -cell receptor engagement3.  Another 
preclinical study using genomic and expression profiling identified spleen tyrosine kinase, a protein upstream from BTK in the B- cell receptor signaling pathway, as a potential therapeutic 
target  for MCL
19.  These observations provided rationale to target the B- cell receptor pathway in 
clinical trials for MCL patients with agents such as ibrutinib.  
 In the i nitial ibrutinib phase I trial that encompassed multiple relapsed and refractory B -cell 
malignancies, seven of the nine MCL patients achieved a response with three complete responses. Pharmacodynamic studies indicated that a fixed continuous dose of 560mg daily  led 
to full BTK  occupancy  in a range of individual body weights and  was well tolerated, leading to 
the selection of this dose for phase II studies
13.  Toxicities were minimal as described above in 
Section 2.3.   In the landmark phase II study, 111 relapsed or refractory MCL patients were treated with 560mg daily of oral ibrutinib
20.  Again, ibrutinib was well tolerated with grade 1 or 2 diarrhea 
(44%), fatigue (37%), and nausea (30%) as the most common adverse events.  An overall response rate of 68% was observed.  The estimated PFS was 13.9 months (95%CI=7.0 to not reached) and the median OS was not reached.  At 18 months, the estimated rate of OS was 58%
20.  Secondary to the response data from this trial, ibrutinib was approved by the US FDA as 
a single- agent in relapsed and refractory MCL patients.  
 In attempt to improve upon the single-agent success of ibrutinib in MCL patients, multiple trials are ongoing with ibrutinib in combination with various immunochemotherapy agents
21, 22.  There 
still remains a great need for combination therapy with ibrutinib and other non-cytotoxic agents, especially for elderly or unfit patients that cannot tolerate these aggressive therapies.   
 2.5 Ibrutinib in Diffuse Large B -cell Lymphoma  
 Diffuse large B -cell lymphoma (DLBCL) is a heterogeneous diagnostic category with multiple 
distinct subtypes.  Patients with the  activated B -cell-like (ABC) subtype of DLBCL have been 
shown to have poor response and survival when treated with standard chemoimmunotherapy regimens
23.  This subtype has been found to rely on constituitive NFκ B signaling to block 
apoptosis24, which is moderated by the signaling adaptor CARD11.  In ~10% of ABC DLBCL, 
CARD11 is mutated to cause this constituitive activation25.  In the ABC DLBCL patients with 
wild-type CARD11, RNA interference genetic screen revealed that BTK is essential for the 
survival of these cells and knockdown of proximal B- cell receptor signaling killed these 
lymphoma cells4.  These data provided preclinical rationale to targeting BTK in ABC DLBCL 
patients.  
 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
11 In the initial phase I study of ibrutinib in relaps ed/refractory hematologic malignancy, two of the 
seven DLBCL patients achieved response
13.  Secondary to preclinical data indicating that the 
ABC subtype is more dependent on the B-cell receptor signaling pathway, a phase II study was designed to test the hypothesis that ibrutinib would be more active in these patients than an alternative germinal center B -cell-like (GCB) subtype
26.  Seventy patients with 
relapsed/refractor y DLBCL enrolled on the trial received 560 mg of oral ibrutinib daily.  Of the 
25 evaluable ABC DLBCL patients, 10 (40%) achieved response with 2 (8%) complete responses.  In the ABC DLBCL responders, the median PFS was 5.5 months at the time of analysis.  In contrast, only 1 of the 19 (5.3%) GCB DLBCL patients achieved a partial response.  The results of this trial were consistent with an essential role of B -cell receptor signaling in ABC 
DLBCL patients
26.  As t he response rate was 40% in these patients, there is room to augment the 
success of ibrutinib in these patients via combini ng this agent with other agents with alternative 
targets and mechanism of action .    
 2.6 Tumor Suppressor Protein (TSP) and Growth Regulatory Protein (GRP) Nuclear 
Export  
 
Many  important TSP/GRPs have been identified in cancer pathogenesis, including but not 
limited to TP53, FOXO3a, iκB, BRCA1, APC, and Rb
27. TSP/GRPs mediate tumor suppression 
pathways via various functions including recognition of cellular damage, arrest of the cell cycle until repairs can be made, and induction of apoptosis in cells that are beyond repair
28.   
 These proteins function primarily in the nucleus and exportation out of the nucleus can inactivate their abilities to regulate cellular processes
29 and cancer cells can exploit these normal functions 
to successfully evade anti -neoplastic therapy . The majority of known TSP/GRPs must traverse 
structures imbedded in the nuclear envelope called nuclear pore complexes (NPC)27.  One 
primary component of the NPC is called chromosomal region maintenance protein 1 (CRM1) in mice or exportin 1 ( XPO1)  in humans
27.  XPO1  can identify these cargo proteins (including 
TSP/GRPs)  via canonical Nuclear Export Sequences (NES), which are typically leucine- rich 
repeats in the cargo protein, which are exposed on the protein surface in response to microenvironment signals
29.  Once the cargo protein forms a complex with XPO1 (CRM1)  and 
RanGTP (energy source) the protein can be transported out of the nucleus
30, in a 
process promoted by Ran-binding protein RanBP3
27 (as shown in Figure 1).   XPO1  
overexpression has been reported in many types of human cancer, including both solid tumors and hematologic malignancies
27.  XPO1  overexpression 
and subsequent increased export and inactivation of TSP/CRPs may fuel the growth of these cancers and lead to chemotherapy resistance.  
 

OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
12 2.7 Inhib ition of XPO 1 in Human Cancer  
 
FOXO3  is a transcription factor that is a crucial regulator of hematopoietic cell fate that plays a 
role in proliferation and apoptosis as a component of the phosphatidylinositol 3- kinase 
(PI3K)/AKT pathway
31 that is commonly activated in various cancers.  FOXO3 was found to be 
constitutively inactivated in mantle cell lymphoma cell lines and to have cytoplasmic localization in patient- derived cells
31.  These FOXO3 defective cells were resistant to PI3K/AKT inhibitors 
in vitro31.  Non -specific i nhibition of nuclear export with a non- specific small molecule 
(Psammaplysene A ), drastically reduced viability of the malignant cells and made those cells 
more susceptible to cytotoxicity from doxorubicin31.  Another group showed that plasmid -based 
overexpression of constitutively active FOXO3 in cells from chronic lymphocytic leukemia (CLL) reduced their survival
32. 
 Based on the suspected mechanism of CRM1 in driving malignancy  and chemotherapy 
resistance, the molecule is promising as an oncologic therapeutic target.  CRM1 blockade of causes a transient nuclear retention of TSP/GRPs, re -establishing their tumor suppressing effects 
on cancer cells and potentially reversing mech anisms leading to chemotherapy resistance (which 
holds possible future implications for combination therapies)
33.  In normal cells, XPO1 inhibition 
transiently arrests cell cycle without cytotoxicity followed by recovery  after the inhibitor is 
removed33.  Several attempts to develop this class of anti- cancer drug have failed secondary to 
off target effects of the drugs, which led to significant fatigue and weight loss in the early clini cal 
trials34-36. 
 2.8 Selective Inhibitors of Nuclear Export (SINE ) 
 
SINE, a new generation of CRM1/XPO1 inhibitors, was designed to more selectively inhibit XPO1 for increased efficacy and reduced toxicity secondary to off- target effects.  KPT -185 and 
KPT -251, two SINEs, were initially evaluated for CLL in our laboratory a t Ohio State University 
(OSU)
37.  These data showed that the SINEs induced significant time and dose-dependent 
cytotoxicity in CLL cells (even in patient  samples with known poor prognostic factors such as 
unmutated IgVH status), while causing only modest apoptosis in normal B- cells37.  In CLL cells, 
the SINEs demonstrated specific inhibition of nuclear export via analysis of increased accumulation of important TSP/GRPs (AKT, p53, FOXO3a, and IκB) in the nucleus
37.  In a 
mouse model of CLL (Eµ- TCL1 -SCID mouse), treatment with KPT -251 showed a significant 
improvement over survival when compared to fludarabine- or vehicle- treated mice.  The drug 
was well tolerated, resulting on only moderate wt loss (≤10% of body wt)37.  Another group 
studied SINEs (KPT-185 and KPT-276) in mantle cell lymphoma (MCL), an aggressive subtype of non-Hodgkin’s (NHL) B -cell lymphoma
38.  In MCL cell lines and primary cells, the SINEs 
induced significant apoptosis in a manner independent of p53 status38.  Oral administration of 
KPT -276 significantly suppressed tumor growth in a MCL- bearing SCID mouse, with minimal 
wt loss and no other clinically observed toxicities38.  Another similar SINE (KPT -335) was 
administered to dogs with spontaneous NHL at doses up to 2mg/kg twice weekly39.  This single-
agent therapy demonstrated disease stabilization and tumor reduction with a main side effect of anorexia, which was largely overcome by food supplementation
39.  Secondary to the success of 
these SINEs in preclinical study, selinexor ( KPT -330) was developed with the goal of improved 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
13 pharmacokinetic (PK) and oral bioavailability.   2.9 Selinexor Preclinical and Clinical Data  
 
Selinexor, the newest generation of SINE, has been tested in our lab and in our clinics with a nearly complete phase I study in advanced hematologic malignancy.  In CLL cells, selinexor induced similar levels of cytotoxicity while preserving normal B- cells when compared to KPT-
251
40.  The compound also showed enhanced cytotoxicity in high-risk CLL cells including 
patien t samples with del(17p) cytogenetics and unmutated IgVH status40.  In CLL patient 
samples with unmutated IgVH status, XPO1 inhibition prevents CpG-induced phosphorylation of ERK and AKT, thereby preventing expression of cMyc and cyclin A2 and downstream proliferation of these CLL cells.  SINEs induce BTK downmodultion in CLL cells.  Selinexor abrogated phosphorylation of AKT and ERK in primary CLL cells, possibly through targeted inhibition of AKT or ERK pathways
40.  Additionally, selinexor was found to significant ly inhibit 
CXCL12 -mediated signaling in CLL cells, which prevents trafficking of CLL cells to the 
protective stromal environment and decreases the cells ability to survive40. 
 In Eµ -TCL1 -SCID mouse model of CLL, mice were treated with selinexor  either twice (BIW; 5 
or 15mg/mL) or thrice (TIW; 3 or 10mg/mL) weekly and compared with vehicle -treated mice for 
36 weeks.  The mice treated with 15mg/mL BIW and all mice treated TIW, showed significant survival improvement over vehicle
40.  Additionally, selinexor was well -tolerated with initial 
weight loss, which was fully reversed by the end of the study and did not appear to adversely 
affect the animals40.  
 Preclinical PK and toxicology parameters have been studied in mouse (CD1), rat (Sprague-Dawley), and monkey (cynomolgus) models (unpublished data from Karyopharm Therapeutics, Natick, MA).  Oral bioavailability was consistently >60% in all species.  Based on these studies and work with similar compounds in dogs, the minimal area under the curve (AUC) values were determined to be ~5,000ng*hr/mL in mice and ~2,000ng*hr/mL in dogs.  These values correspond to anticipate d AUC values of >3,000ng*hr/mL in humans, which should be achieved 
at projected doses of 15- 45mg/m
2.  In toxicology studies, the rats and monkeys demonstrated a 
dose limiting toxicity (DLT) of wt loss with atrophy of the gastrointestinal tract and noncritical effects on other major organs.  Majority of adverse events (AEs) were completely reversed after a 2-week break period. At projected doses of ≤45mg/m
2, observed AEs were rare.  For the rats, 
the severely toxic dose (STD) was found to be 30mg/m2 and for monkeys, the highest non-
severely toxic dose (HNSTD) was 18mg/m2.  Therefore, based on International Conference in 
Harmonization (ICH) guidelines, the initial starting dose for selinexor  humans in the phase I trial 
was 3mg/m2 (rat STD/10=3mg/m2; monkey HNS TD/6=3mg/m2). 
 
Selinexor is currently under clinical investigation for the treatment of patients with advanced hematologic and advanced solid malignancies. Three Phase 1 studies (KCP -330-001 in 
hematologic malignancies, KCP-330-002 in solid tumor malignanc ies, KCP -330-00: food effect 
in sarcoma)  are in progress.   In addition, Phase 2 studies in multiple hematologic and solid 
tumor indications are currently ongoing or in process of being initiated (protocol submitted to FDA).   These studies and current safety and efficacy results are described in detail in the 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
14 Investigator’s Brochure.  In a food effect study, the presence of food (high- or low-fat meals) delayed selinexor absorption (tmax from 1.7 to approximately 4 hours), however, there was minimal impact on exposures (geometric mean ratio [GMR] was 114.7% and 125.5% for low- and high- fat meals, 
respectively) and this was not clinically relevant. Therefore, selinexor should be taken with water and can be administered with or without food. 
To date, broad ant i-tumor activity has been reported during the dose -escalation phase with single 
agent selinexor in patients heavily pretreated, with relapsed/refractory, progressive solid tumor 
and hematologic malignancies. The most common adverse effects (AEs) have been similar to those reported in nonclinical studies and include anorexia, weight loss, nausea and fatigue. These AEs can be prevented or mitigated with dietary counselling and prophylactic supportive medications.  No major organ toxicities have been observed to date, and no clinically significant cumulative toxicities have been observed in >10 months of dosing.  Overall, oral selinexor pharmacokinetics was predictable, reasonably dose -proportional, and exhibited moderate to moderately high inter -
patient variab ility across a wide dose range in male and female patients with advanced solid tumor 
or hematological malignancies.  
The phase I study in advanced hematologic malignancies ( KCP -330-001) is ongoing at multiple  
institution s, with 148 patients enrolled as of 28 February 2014. Of the 68 patients assessed for 
efficacy in Arm 1 (B cell malignancies) as of 28 February 2014, 55 patients (81%) had partial 
response s (14 patients, 21%), minimal response s (6 patients, 9%), or stable disease ( 35 patients, 
51%).  A total of 13 patients  (19%) had progressive disease.  These data are summarized in the 
table below.  
Best Resp onses in Patients with B Cell Malignancies in KCP -330-001 as of 28 February 
2014  
Cancer Type  Number of 
Patients 
Evaluated  Total PRs, 
MRs and 
SD (%)  PR (%) MR (%)  SD (%)  PD (%) 
Multiple Myeloma  28 22 (79%)  1 (4%)  4 (14%)  17 (61%)  6 (35%)  
CLL  4 4 (100%)  2* (50%)  -- 2 (50%)  -- 
Richter’s 
Transformation  4 3 (100%)  1 (25%)  -- 2 (50%)  1 (25%)  
Other types  1 1 (100%)  -- -- 1 (100%)  -- 
Non-Hodgkin’s lymphoma s      
Diffuse Large B 
Cell Lymphoma  18 13 (72%) 5 (28%) -- 8 (44%) 5 (28%) 
Follicular 
Lymphoma  6 6 (100%)  1 (17%)  -- 5 (83%)  -- 
Mantle Cell 
Lymphoma  2 2 (100%)  1 (50%)  -- 1 (50%)  -- 
Transformed 
DLBCL  3 1 (33%)  1 (33%)  -- -- 2 (67%)  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
15 Waldenstrom’s 
Macroglobulinemia  3 3 (100%)  1 (33%)  2 (67%)  -- -- 
Total  68 55 (81%) 14 (21%) 6 (9%)  36 (5 1%) 13 (19%) 
Abbreviations: PR=partial response, MR=minimal response, SD=stable disease, PD=progressive disease, NE=not 
evaluable, WC=withdrew consent.  *These PRs in CLL patients refer to Lymph Node responses only.  
 
In summary, this early analysis has also demonstrated tolerability and preliminary signals of response in the hematologic malignancies population (unpublished data Karyopharm). Constitutional symptoms of weight loss, fatigue, and anorexia were common but can be prevented or mitigated using aggressive prophylactic supportive measures.   
 2.10 Rationale for the Study  
 
Although ibrutinib has shown signific ant efficacy in CLL and NHL as a single agent, relapses 
have occurred via binding site mutations and certain subgroups of each disease continue to lag in PFS.  Additionally, this treatment requires continuous treatment and does not produce complete remissi ons.  Thus, efforts to diminish the frequency of ibrutinib relapse and also increase the 
depth of remission with combination based therapies is a priority moving forward in the field of 
CLL and NHL.  In both CLL and NHL the importance of BTK as a true ther apeutic target has 
been genetically, pharmacologically, and clinically validated.  Preclinical and clinical data have 
shown that CLL and NHL are susceptible to single-agent cytotoxicity by selinexor. Selinexor has been shown to inhibit the BCR pathway in an alternate way than ibrutinib by depleting BTK protein level, which provides rationale to combine these drugs.  Indeed, targeting a kinase/protein/pathway in two or more different ways is a classic pharmacologic strategy to prevent emergence of drug resis tance.  In phase I clinical trials in this population, selinexor has 
shown tolerability and early signals of clinical efficacy.  Ibrutinib which is approved for NHL and CLL has similar promising results.  We hypothesize the combination will be active and tolerable in this population and want to proceed with phase I investigation.  Ultimately, we anticipate this approach moving to larger randomized phase II trials comparing the combination treatment to monotherapy with ibrutinib.  
 2.11 Rationale for the Dose/Dosi ng Schedule  
 
Recent analysis of the existing PK data from Phase 1 trials KCP -330-001 and KCP-330-002 
supports the use of fixed rather than BSA-based dosing. The 5
th and 95th percentile for BSA 
values encountered to date in Phase 1 trials KCP-330-001 and KCP-330-002 are 1.5 and 2.3 m2, 
respectively (N=331). PK values (C max and AUC(0-∞)) for a given flat (fixed) dose of selinexor 
were similar across this typical BSA range, indicating that exposure is not strongly correlated with BSA.   
 In Phase I study, the lowest dose that selinexor inhibits XPO1 completely for ~24 hours is 12mg/m
2  (about 20 mg) on a 10 doses per cycle schedule, however,  prolonged inhibition of 
XPO1 mRNA were observed at doses >23 mg/m2, allowing twice weekly dosing.   Therefore , 40 
mg weekly will be our lowest dose administered, with goals to use twice weekly dosing if 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
16 tolerated.  The phase I study has reached a dose level of 60mg/m
2 twice weekly, and our 
proposed study’s top dose level (100 mg twice weekly) is equivalent to this dose .   We are 
starting at this lower dose of selinexor to assure tolerability of the combination.     The starting dose of 420 mg of ibrutinib for CLL patients is based on the standard recommended dosing from the phase II study of patients with relapsed/refractory CLL.   In this study, correlative analyses demonstrated a greater than 90% occu pancy of the pharmacodynamics BTK 
probe and similar response rates between the groups that received 420 mg and 840 mg, which provided support for the use of the 420 mg dose in CLL patients
8.   
 The starting dose of 560 mg of ibrutinib for NHL patients is based on the standard recommended dosing from the phase I study of patients with relapsed/refractory lymphoid malignancies.  In 
this trial, pharmacodynamic studies indicated that a fixed continuous dose of 560mg daily  led to 
full BTK  occupancy  in a range of individual body weights and  was well tolerated, leading to the 
selection of this dose for phase II studies
13.   
 2.12 Correlative Studies Background  
 We plan to evaluate the inhibition of the B- cell receptor signaling pathway via assessment of 
phosphorylation of BTK, PLc ᵧ, AKT, and ERK in patients with relapsed or refractory CLL who 
receive the combination of selinexor and ibrutinib.  In primary CLL cells, ibrutinib has been shown to inhibit these components of the B-cell receptor signaling pathway
12.   In CLL patient 
samples with unmutated IgVH status, XPO1 inhibition  with selinexor prevents CpG-induced 
phosphorylation of ERK and AKT, thereby preventing expression of cMyc and cyclin A2 and downstream proliferation of these CLL cells.  Selinexor induced BTK downmodulation in CLL cells.  Selinexor abrogated phosphorylation of AKT and ERK in primary CLL cells, possibly through targeted inhibition of AKT or ERK pathways
40.  Evaluation of B- cell receptor pathway 
inhibition in patients on this trial will provide evidence for potential drug synergy or interactions.  We plan t o evaluate the change in localization of tumor suppressor proteins in patients with 
relapsed or refractory CLL following treatment with selinexor with the aid of confocal microscopy and immunoblot of downstream targets of these proteins (NFKB, Mcl1, Tcl1, BTK, p21, BCLxL, cMyc ).   As  selinexor inhibits the exportation of nuclear tumor suppressor 
proteins
40, this correlative study will allow exploratory investigation of potential drug 
interactions on this clinical trial.     Baseline characte ristics of tumor samples, plasma and microenvironment will be assessed at 
baseline to preliminary examine for features of primary resistance. For patients who respond to therapy and then relapse, we will characterize the features of resistance to ibrutinib  and 
selinexor.  As both of these are irreversible inhibitors, we will focus on the primary target (BTK, XPO1) and  also down- stream molecules (PLCγ 2) .  We will also take a more global approach 
through examination of next generation sequencing methods examining the genome, transcriptome, and epigenetic changes from baseline samples to those obtained at relapse.   Expression and biochemical studies of pathways of resistance will also be pursued.  For CLL this will be done on blood, bone marrow aspirate, and lymph nodes (when available).  For NHL, this 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
17 will be examined predominately from nodal material (including archival material if available from previous biopsy) along with blood/marrow if positive for NHL.   Buccal swabs or other germ line material (marrow fibroblasts, saliva) will be collected for interpretation of next generation sequencing data differentiation of SNP versus acquired mutations.    We also plan to characterize plasma pharmacokinetics of selinexor and steady -state plasma 
concentrations of ibrutinib. We will compare selinexor pharmacokinetics (full 24-hour profiles) in the absence and presence of ibrutinib, and we will compare ibrutinib steady state concentrations with historical data to identify any significant differences in pharmacokinetics since there is a small potential for drug -drug interactions via CYP3A4/5. We will also 
characterize concentration vs. time of selinexor in white blood cells. These cells will be obtained from samples collected at the same time points as the plasma pharmac okinetic samples for 
selinexor. Given KPT-330 chemically reacts with glutathione and may also be metabolized to form glutathione and glucuronide conjugates, we hypothesize intracellular conjugation will vary among patients, and intracellular selinexor exposures will better correlate with pharmacodynamic measures and clinical response to this agent relative to plasma exposures. In addition to selinexor, we will also measure and pseudo-quantify selinexor hydroxylated and conjugated (glutathione and glucuronide) metabolites. The ratio of intracellular metabolites to parent drug may be expected to be higher at baseline or to increase during the first few weeks of combined therapy for patients less sensitive or resistant to selinexor.  A single whole blood sample or lymph node aspirate and buccal swab will be obtained for DNA extraction. DNA will be extracted and stored for potential analysis later if patients relapse on therapy or if relevant pharmacogenetic questions arise during clinical development of selinexor.  3. PATIENT SELECTION  
 3.1 Eligibility Criteria   
 
3.1.1 Patients must have : 
 
• A histologically confirmed diagnosis of CLL/SLL/B -cell PLL  according the International 
Workshop on CLL /SLL/ B-cell PLL or variant of these [IWCLL
14 or World Health 
Organization  (WHO ) Criteria ] and meet criteria for treatment  or have need for 
cytoreduction for stem cell transplantation or alternative cell therapy . 
 
OR 
 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
18 A histologically confirmed diagnosis of mantle cell lymphoma (MCL) or di ffuse large B -
cell lymphoma  (DLBCL) de novo or in the setting of transformation from an indolent 
lymphoma (including DLBCL not otherwise specified) according to the World Health Organizatio n criteria for diagnosis of NHL.  
 
AND  
 
• Patients must have received at least one prior therapy  for CLL or NHL , need additional 
treatment  (or have need for cytoreduction as mentioned above) , and meet criteria for 
relapsed or refractory disease. They may not be a candidate for curative therapy.  Relapsed disease is defined as a patient who previously achieved a CR or a PR, but after a period of six or more months demonstrates evidence of disease progression. Refractory disease is defined as progression within six months of the last anti- leukemic or anti-
lymphoma ther apy, or any response less than a CR or PR.   
EXCEPT  
• Patients in Cohort 3 (selinexor added to ibrutinib for patients receiving frontline therapy) must be receiving ibrutinib as their initial therapy for CLL or SLL. These patients must have been receiving ibrutinib for at least 1 year before enrollment  
3.1.2 Patients must be ≥ 18 years of age.  
 
3.1.3 Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of < 2.  (See Appendix A.) 
 
3.1.4 Patients with NHL must have objective, documented evidence of disease prior to study entry. 
 
3.1.5 Patients must have normal organ function defined as:   
• Platelet count ≥ 50,000/mm
3 in the absence of bone marrow involvement ; 
patients with bone marrow involvement only require a platelet count of > 
30,000/mm3 
• Absolute neutrophil count ≥ 1000/mm3 in the absence of bone marrow 
involvement ; patients with bone marrow involvement are not required to have 
a minimum absolute neutrophil count 
• Creatinine  clearance [ as calculated by Cockroft Gault equation =(140- age) * 
Mass (kg) *(0.85 if female) /(72 * creatinine mg/dL]  ≥ 30mL/min  
• AST/ALT < 2.5 times upper limit of normal (ULN)  
• Total bilirubin ≤ 2.0 x ULN. 
 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
19 3.1.6 Female patients capable of repro duction and male patients who have partners capable 
of reproduction must agree to use an effective contraceptive method during the course of the study and for -1 month  following the completion of their last treatment.  
Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. 
 
3.1.7 Female of childbearing poten tial must have a negative serum β -Hcg pregnancy test 
result within 3 days of first study dose.  Female patients who are surgically sterilized or who are > 45 years old and have not experienced menses for > 2 years may have β -
Hcg pregnancy test waived.  
 
3.1.8 Patients with a history of hepatitis B (surface antigen or core antibody positive and 
PCR positive) must take lamivudine or equivalent drug during study therapy and for one year after completion of all therapy.  Patients on IVIG who are core antibody positive but PCR negative are not mandated to take prophylaxis. 
 
3.1.9 Ability to understand and the willingness to sign a written informed consent document. 
 3.1.10 Patients enrolled into cohort 3 must have high-risk disease with higher risk of relapse on ibrutinib.  This includes patients with complex karyotype (3 or more cytogenetic abnormalities) or high/very high risk by CLL -IPI (https://www.mdcalc.com/international-prognostic-index-
chronic-lymphocytic- leukemia- cll-ipi) 
 
3.2 Exclusion Criteria  
 
3.2.1 Patients who  are concurrently  receiving any other investigational agents. 
 
3.2.2 Patients who have received:  
-Radiation or chemotherapy ≤ 4 weeks,  
-Mitomycin C , nitrosureas, or radio -immunotherapy ≤ 6 weeks, or  
-Immunotherapy or targeted therapy (such as kinase inhibitors) ≤2 w eeks prior to 
cycle 1 day 1 . Patients who are on ibrutinib at study entry are not required to 
discontinue ibrutinib for any period of time.  
Palliative steroids for disease re lated symptoms are allowed as long as dose is tapered 
down to an equivalent of ≤ 10mg of oral prednisone daily on cycle 1 day 1.   
3.2.3 Patients who have underwent autologous or allogeneic stem cell transplant ≤ 4 weeks prior to cycle 1 day 1 or have active graft-versus- host disease are excluded.  
 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
20 3.2.4 Patients unable to swallow tablets or capsules , those with uncontrolled vomiting or 
diarrhea  or disease significantly affecting g astrointestinal function and/or inhibiting 
small intestine absorption such as; malabsorption syndrome, resection of the small bowel, or poorly controlled inflammatory bowel disease affecting the small intestine  
 
3.2.5 Patients who are 20% below their ideal body weight (BMI calculator can be found at 
http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/english_bmi_calculator/b
mi_calculator.html)  
  
3.2.6 Patients must not be receiving systemic anticoagulation with warfarin.  Patients must be off warfarin for 30 days prior to enrollment.  Patients who require anticoagulation with an agent other than warfarin will not be excluded, but must be reviewed by the principal investigator prior to enrol lment.  
 
3.2.7 As ibrutinib is extensively metabolized by CYP3A4/5, and patients must not require continued therapy with a strong inhibitor or inducer of CYP3A4/5.  See Appendix B for a list of these medications.  
 
3.2.8 Patients with active HIV or Hepatitis C.  (HIV -positive patients on combination 
antiretroviral therapy or Hepatitis C -positive patients on antiviral therapy are 
ineligible because of the potential for pharmacokineti c interactions with ibrutinib or 
selinexor.  In addition, HIV patients are at increased ri sk of lethal infections when 
treated with  potentially  marrow -suppressive therapy.) 
 
3.2.9 Patients with secondary malignancy that requires active systemic therapy that will interfere with interpretation of efficacy or toxicity of selinexor .  (Note:  Patients with 
basal or squamous skin carcinoma, cervical carcinoma in situ, localized breast cancer requiring hormonal therapy or localized prostate cancer (Gleason score <5 are allowed).  
 
3.2.10 Patients with active known central nervous system (CNS) involvement of CLL or lymphoma.  (Patients with history of CNS CLL or lymphoma now in remission are eligible for the trial.)  
 
3.2.11 Patients who are pregnant or breast feeding.  (Pregnant women are excluded from this study because it is unknown if selinexor has teratogenic or abortifa cient effects.  
Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with selinexor , breastfeeding should be 
discontinued if the mother is treated with  selinexor.) 
 
3.2.12 Patients must have recovered all toxicities from prior therapy or radiation to grade 1 or less (excluding alopecia).  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
21 3.2.13 Patients may not have had major surgery within 10 days of enrollment, or minor surgery within 7 days of enrollment. Examples of minor surgery include dental surgery, insertion of a venous access device, skin biopsy, or aspiration of a joint. The decision about whether a surgery is major or minor can be made at the discretion of the treating physician.  
3.2.14 Patients with u ncontrolled intercurrent illness including, but not limited to, ongoing 
or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 
3.2.15 Patients e nrolling in Cohort 3 must not have ongoing Grade 3 or higher toxicity 
due to ibrutinib at study entry (except hypertension that is medically managed).  
 
  3.3 Inclusion of Women and Minorities  
 Both men and women of all races and ethnic groups are eligible for this trial.  
  4. REGISTRATION PROCEDURES  
For subsite patients, sites must send the signed consent form, documentation of the consent process, and the Screening Form (refer to Supplemental Forms Document) within 2 business days of initial consent.  
 Patients will be registered after meeting all entry requirements, clearance by the Protocol Coordinator, and signing of the informed consent.  OSU patients will be registered by the OSU research coordinator, as per their standard practice.  
 Subsite patients will have eligibility verified and will be entered on study centrally at the Oh
io State University  by the Multi- Center Trial  Program (MCTP_ . All subsites must email 
the MCTP  to verify slot availability prior to consenting patients. The required forms, 
including Eligibility Criteria Checklist and Registration Form, can be found in the Supplemental Forms Document.  To r
egister a subsite patient, the following documents must be completed by the subsite 
research team and faxed or securely e- mailed to the MCTP : 
• Copy of all baseline tests required per the protocol calendar. Tests must be within the specified window. 
• Signed Patient Consent Form 
• Signed Patient HIPAA Authorization Form 
• Consent Documentation Note 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
22 • Completed & Signed Eligibility Checklist (refe r to Supplemental Forms 
Document) 
• Registration Form (refer to Supplemental Forms Document) 
• Source documents verifying every inclusion & exclusion criteria 
o Note: every inclusion and exclusion criteria must be documented in the patient’s medical record (emails or other notes outside the medical 
record will not be considered source documentation) 
 Upon receipt of registration documents, the MCTP  will send an email confirmation of 
receipt. If confirmation of receipt is not received within 1 hour of submission, please call or page the MCTP . 
 Upon receipt of all required registration documents and upon verification the subsite patient meets all eligibility criteria, the MCTP  will:  
• Register the patient on the study 
• Fax and/or e -mail to the subsite the completed Registration Form with the 
assigned study ID as confirmation of patient registration 
 Following registration, patients should begin protocol treatment within 7 business days.
  
Issues that would cause treatment delays should be discussed with the Principa l Investigator 
and MCTP  as soon as possible. If a patient does not receive protocol therapy following 
registration, the patient’s registration on the study may be canceled, after discussion with the PI and MCTP . 
 Each participating institution will order s tudy agents directly.  Agents may be ordered by a 
participating site only after the initial IRB approval for the site has been forwarded to the MCTP . 
 
  5. TREATMENT  
 5.1 Overview  
 The study will enroll patients with CLL and NHL in a dose escalation and subsequent expansion.  
First, patients with relapsed or refractory disease will be enrolled in a dose finding study that will 
assign doses for each patient using a modified continuous reassessment method using soft ware 
developed by Piantadosi (Modified Continual Reassessment Method, version 4.0). Up to  10 
patients with CLL and 10 patients with NHL will be treated at the estimated MTD  as part of the 
expansion.  In August 2016 after 2 patients were treated at dose lev el 2 for 1 cycle, both reported significant 
fatigue and anorexia.  While not technically DLT, these AEs were concerning to the investigators, and after discussion with the DSMC it was decided to return to dose level 1 for continued expansion.  This was discussed with Karyopharm, who reported increased tolerability 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
23 and efficacy using once weekly dosing strategies in other studies.    Cohort 3, which will initiate after the dose escalation and expansion, will add selinexor administered weekly (days 1, 8, and 15 of each cycle) at 40 mg PO, to patients receiving ibrutinib as frontline therapy for at least 12 months.  Selinexor plus ibrutinib will be administered for 14 cycles, with discontinuation of selinexor after 14 cycles.  At the end of 14 cycles, patients who a chieve a minimal residual disease (MRD) negative response may have both drugs 
discontinued at the discretion of the treating physician.  Patients who are MRD positive at the end of 14 cycles will discontinue selinexor and are recommended to continue ibrutinib.        5.2 Agent Administration  
 Treatment will be administered on an outpatient basis.  Reported adverse events and potential risks are described in Secti on 7.  Appropriate dose modifications are described in Section 5.  No 
investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's malignancy.  
 
Regimen Description  
Agent  Precautions  Dose  Route  Schedule  Cycle Length  
Ibrutinib  Take with 8 oz of water, 
30 min before meal Capsule  
or 
tablet* Oral Cycle 1 Days 8 -
28**, Cycles 2+ 
Days 1 -28 28 days (4 
weeks)  
Selinexor  Take with at least 120 
mL (4 ounces) of fluids 
(water, juice, etc.)  Tablet* Oral Days 1, 8, and 15 of 
each cycle* 
*Doses/schedule as appropriate for assigned dose level.  
**Patients continuing on ibrutinib should take ibrutinib days 1- 28 of Cycle 1  
 
 
Dose 
Level  Selinexor 
Dose  Selinexor 
Schedule  Ibrutinib 
Dose   Ibrutinib 
Schedule  
1* 40 mg  Weekly (oral)  420 mg Daily (oral)  
2 20 mg  Bi-weekly (oral)  420 mg Daily (oral)  
   
5.2.1 Study Drugs Description 
 5.2.1.1 Selinexor is an oral selective inhibitor of nuclear export.   
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
24 Selinexor is manufactured by KABS Laboratories (Montreal, ON) for Karyopharm, Therapeutics (Newton, MA) using methods in accordance with Food and Drug Administration (FDA) guidelines for the manufacture and testing of antineoplastic agents for human use.  The tablets are prepared from a common blend of excipients and all tablet excipients are GRAS (generally regarded as safe) listed and suitable for use in pharmaceuticals.  Selinexor is an investigational agent supplied to investigators 
of this study by Karyopharm Therapeutics at no cost.  
 5.2.1.2 Ibrutinib  is an oral  inhibitor of Bruton’s tyrosine kinase.  The compound is 
manufactured by Pharmacyclics, Inc ( Sunnyvale, CA ) using methods in accordance 
with Food and Drug Administration (FDA) guidelines for the manufacture and testing of antineoplastic agents for human use.   
 5.2.2 Drug Products Composition and Preparation 
 5.2.2.1 Selinexor 
Selinexor will be supplied in 20 mg tablets in wallet- sized blister packs (12 tablets per blister 
pack).  Each wallet -size blister package of selinexor tablets will be labeled in accordance with 
current International Conference on Harmonization (ICH), Good Clinical Practice (GCP), and specific regulatory requirements, e.g., FDA, Health Canada, EMA, etc.  Blister packages for take-home use may require additional in-pharmacy labeling with take-home and patient- specific 
instructions (such as exact dose) depending on country- specific regulations or laws.  
 5.2.2.2 Ibrutinib   
 Ibrutinib for oral administration is supplied as either capsules or tablets.  The capsules are hard gelatin capsules containing micronized ibrutinib and the following excipients: microcrystalline cellulose; croscarmellose sodium; sodium lauryl sulfate; may contain magnesium stearate. Capsules are manufactured as 140mg in a size 0, gray, hard gelatin capsule. Capsules are packaged in high-density polyethylene (HDPE) bottles with an induction seal and a child resistant screw top cap. Each bottle contains 92 capsules. Ibrutinib capsules are to be dispensed in their original containers.  The tablet formulation is manufactured as 140, 280, or 420 mg and is dispensed as a blister pack.  
 5.2.3 Selinexor Administration  
 Each dose will consist of selinexor tablet(s) for oral administration on a fixed dose basis.  Dose levels for the study are 40 mg once weekly and 20 mg twice weekly.  If needed, the level (- 1) de -
escalation dose level will be 20 mg weekly .  Selinexor oral doses are given Days 1, 8, and 15 of 
each 28 day cycle.  
 
Selinexor tablets are to be taken with at least 120 mL (4 ounces) of fluids (water, juice , etc.)  at 
approximately the same time each day .  Selinexor tablets should not be crushed because of 
increased risk of dermatologic toxicity if the powder comes in contact with skin. 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
25  5.2.4 Ibrutinib Administration  
 Ibrutinib should be taken with 8 ounces (approximately 240 mL) of water (avoid grapefruit or Seville orange juice due to CYP450 3A4 inhibition). Each dose of ibrutinib should be taken at least 30 minutes before meal, at approximately the same time each day. The capsules  or tablets  
should be swallowed intact and subjects should not attempt to open capsules or dissolve them in water.   
 If a dose is missed, it can be taken up to 6 hours after the scheduled time with a return to the normal schedule the following day. If it has been greater than 6 hours, the dose should not be taken and the subject should take the next dose at the scheduled time the next day. The missed dose will not be made up and must be reported  at the next scheduled visit. 
 Ibrutinib should be held for any procedure using the following guidelines:   
• For any surgery or invasive procedure requiring sutures or staples for closure, ibrutinib should be held at least 7 days prior to the intervention and should be held at least 7 days after the procedure and restarted at the discretion of the investigator when the surgical site is reasonably healed without serosanguineous drainage or the need for drainage tubes.  
• For minor procedures (i.e. such as a central line placement, needle biopsy, thoracentesis, or paracentesis) ibrutinib should be held for at least 3 days prior to the procedure and should not be restarted for at least 3 days after the procedure. For bone marrow biopsies that are performed while the subject is on ibrutinib, it is not necessary to hold ibrutinib for these procedures.  
• For emergency procedures, ibrutinib should be held after the procedure until the surgical site is reasonably healed, for at least 7 days after the urgent surgical procedure. 
 
5.2.5 Patient Compliance and Replacement  
 To the extent possible, patients must strictly follow the standard dosing schedule. Patients who miss 2 of the doses of selinexor or 1/4 of the doses of ibrutinib within the first cycle of treatment  
in the absence of study drug related toxicity will be discontinued unless these are consecutively missed doses due to a required medical procedure that is unrelated to study drug or an anticipated personal emergency, in which cas e they should restart the cycle.  
 Compliance to study medication will be ascertained  by use of patient diaries for the days where 
patient administers the study drug themselves at home and for the drug administration days in the clinic, compliance to study medication will be done by the investigator or delegate and recorded in source documents. The date, time and number of capsules or tablets consumed will be recorded as per study drug schedule. The principal investigator or the designee will account for the number of capsules or tablets  dispensed against those returned by the patient. Any deviations 
and missed doses will be recorded in the case report form  and drug accountability logs for 
verification with the reasons. The investigator / designee will try to ensure complete compliance 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
26 with the dosing schedule by providing timely instructions to the patients. Patients withdrawn in cycle 1 because of non -compliance not related to study drug related toxicity will be replaced. 
 5.3 Definition of Dose Limiting Toxicity  
 CTCAE version 4.0 is used to grade all adverse events and to provide management guidelines for administrational toxicity.   A copy of the CTCAE version 4.0 can be downloaded from the CTEP web site http://ctep.cancer.gov/protocolDevelopment/electr onic_applications/ctc.htm.   
  
Definition of DLT for patients receiving selinexor and ibrutinib* 
General  
• Treatment delays > 28 days for any toxicity  
• Any grade 5 toxicity  
Non-hematologic  
• Grade 3 nausea/vomiting or diarrhea lasting for ≥7 days while taking optimal 
supportive medications# 
• Grade 3 anorexia or fatigue lasting for ≥7 days while taking optimal supportive care# and with correction of dehydration, anemia, endocrine, or electrolyte abnormalities 
• Grade ≥ 3 AST or ALT elevation lasting for ≥7 days OR any Grade ≥ 3 AST or ALT elevation in the setting of bilirubin elevation > 2x ULN 
• Any other Grade 3 non-hematological toxicity except alopecia, rash that resolves to Grade 1 in ≤ 7 days, or electrolytes abnormalities correctable with supportive therapy# 
Any Grade 4 non -hematologic toxicity not specifically listed above  
Hematologic  
• Grade 4 neutropenia [absolute neutrophil count (ANC) < 500/mm3] (for patients with 
baseline ANC ≥ 1000/mm3) or ≥ 75% reduction of neutrophils (for patients  with 
baseline ANC < 1000/mm3) lasting ≥7 days ; 
• Grade 4 t hrombocytopenia [ platelet cou nt <25,000/mm3] (for patients with baseline 
platelets ≥ 100,000/mm3) ≥ 75% reduction of platelets (for patients with baseline 
platelets < 100,000/mm3)  that persists for ≥7 days;  
• Grade ≥  3 thrombocytopenia- associated bleeding ; or  
• Grade 4  febrile neutropenia (ANC < 1000/mm3 with a single temperature ≥ 38.3ºC or 
sustained temperature of >38°C for over 1 hour).  
*Assessed during Cycle 1 by CTCAEv4 criteria #Section 4.4 provides detailed supportive care ^For patients with 
Gilbert’s syndrome: >2X baseline  
 AEs meeting the above definitions but that are clearly unrelated to study drugs will not be considered DLTs.  Patients will be considered eligible for DLT assessment if they receive at least 2 of 3 planned doses of selinexor and 19 of 21 planned doses of ibrutinib.     In rare instances, an event may fall within the definition of a DLT as defined above, but the event may not be considered a DLT (ie: not clinically meaningful/significant). If this occurs, a meeting 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
27 with all investigators, PI and Sponsor will take place to thoroughly review the event and supporting data and the reasons for not consi dering the event a DLT will be clearly documented 
with supporting rationale. Conversely, other events may occur which do not meet the definition of a DLT but are concerning to the investigators and sponsor and may be then considered to be DLTs.   We will al so consult the DSMC team for input. 
 Management and dose modifications associated with the above adverse events are outlined in Section 5.  Dose escalation will proceed within each cohort according to the following scheme.  Dose-limiting toxicity (DLT) is defined above.    5.4 Concomitant Medications 
 Concomitant medication is defined as any prescription or over-the-counter preparation, including vitamins and supplements. All of a patient’s concomitant medications must be recorded on the case report form from 1 4 days before Day 1 through the end of the patient’s study participation.  
 5.4.1.1 Permitted Concomitant Medications  
 5.5 Prevention of Pregnancy   
 Female patients of child -bearing potential must agree to use dual methods of contraception and 
have a negative serum pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of ch ild-bearing potential. 
Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. For both male and female patients, effective methods of contraception must be used throughout the study and for -one month following the last dose.   5.6 Blood Products   
 During the administration of selinexor and ibrutinib, pati ents may receive red blood cell (RBC) 
or platelet transfusions, if clinically indicated, per institutional guidelines. These transfusions should be leukopore filtered and irradiated.  Patients who require repeated transfusion support should be discussed with the principal investigator.   Patients may receive supportive care with G -CSF or GM -CSF in accordance with institutional 
guidelines prior to entry and throughout the study.   5.7 Radiation Treatment   
 If clinically indicated, palliative radiation therapy to  non- target lesions is permitted but study 
drug should be held for 3-5 days before the start of palliative radiation therapy and 3- 5 days after 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
28 palliative radiation therapy. Treatment with selinexor and ibrutinib shall not be discontinued solely due to palliative radiation.   Additionally for patients responding to this treatment, if local 
radiation to a secondary cancer (prostate, skin, DCIS, etc.) is required, this can be considered after discussion with the PI.  5.8 Glucocorticoid Therapy   
 Glucocorticoids ≤ 10 mg oral prednisone (or equivalent) per day are permitted at baseline and during the study for non-malignant conditions (i.e., asthma, IBD, etc.) as needed.   As part of supportive care (e.g. for nausea or anorexia), oral or parenteral dexamethasone, up to 30 mg/week, may be given to patients, in consultation with the principal investigator. Doses of 2-4mg po qd, or 10mg with each dose of selinexor, can reduce fatigue, increase appetite, and improve energy in patients on study.  5.9 Anti -diarrheal Medications  
 Over -the-counter anti-diarrheal medications (such as loperamide or equivalent) may be used by 
the patient to control loose stools associated with the study medications.  The medications should be used as direct ed by the package insert, pharmacist or treating physician. 
 5.10 General Medications  
 Medications to treat concomitant diseases like diabetes, hypertension, etc. are allowed.   5.11 Procedures  
 Refer to section 5.2.4 for guidelines on holding ibrutinib for procedures.   5.11.1.1 Prohibited Concomitant medications  
 Patients should minimize the use of products containing Acetaminophen. For combination painkillers containing acetaminophen it is recommended that single agent opiates or aspirin combinations (when clinically acceptable) be substituted.   5.12 Anticancer Therapy   
 Concurrent therapy with a systemic approved or investigative anticancer therapeutic, other than glucocorticoids as specified herein, is not allowed (this includes bone marrow transplantation for any reasons).  Hormonal therapy is permitted.   5.13 Investigational Agents   
 Other investigational agents should not be used during the study.   
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
29 5.14 Drugs undergoing Glutathione conjugation  
 The primary metabolism of selinexor in vitro appears to inactivation by glutathione conjugation. This process can be mediated in the absence of p roteins, indicating that it is thermodynamically 
favorable. In vitro studies using human liver microsomes confirm in vivo findings that selinexor undergoes minimal CYP450 metabolism. Therefore, administration of selinexor with drugs which undergo substantial glutathione conjugation should be minimized or avoided. These drugs include acetaminophen (paracetamol). It should be noted that no studies selinexor in combination with acetaminophen have been performed to date and that these recommendations are empiri cal. 
There are no restrictions on the use of acetaminophen or acetaminophen-containing products in combination with selinexor, EXCEPT on days of selinexor dosing, when acetaminophen use must not exceed a total daily dose of 1 g.  5.15 Drugs that inhibit or induce CYP 3A4/5  
 Because there is a potential for interaction of ibrutinib with other concomitantly administered drugs through the cytochrome P450 system, the case report form must capture the concurrent use of all other drugs, over-the-counter medications, or alternative therapies. The Principal Investigator should be alerted if the patient is taking any agent known to affect or with the potential to affect selected CYP450 is oenzymes. Appendix B presents guidelines for identifying 
medications/substances that could potentially interact with ibrutinib.  
 5.16 Warfarin  
 Patients  who  must receive systemic anticoagulation with warfarin  will be excluded secondary to 
severe bleeding when ibrutinb and warfarin have been used concurrently.  Patients must be off warfarin for 30 days prior to enrollment.  If individuals develop a DVT or other complications requiring anticoagulation, low molecular weight heparin or thrombin inhibitors may be used.  Ibrutinib should be held for a minimum of 7 days to assure acceptable tolerance of this treatment.  For patients with low risk atrial fibrillation, aspirin (325 mg/day) is recommended unless the patient is at high risk for thromboembolic complications.   5.17 Concomitant Treatments for Selinexor  
 
Dexamethasone (12  mg) will be given as a concomitant medication with each dose of selinexor.  
For patients with partial intolerance to glucocorticoids, a minimum dose of 8 mg dexa methasone 
is permitted.  Patients who are tolerating selinexor well may have the dose of dexamethasone 
decreased or eliminated at the discretion of the treating physician. Dexamethasone, like the other 
recommended prophylactic treatments in this study, is an approved drug.  It will be provided in tablet form by prescription from the treating physician and obtained from the clinic pharmacy. 
Required 5-HT3 Antagonists:  In order to minimize nausea, unless contraindicated, all patients 
must receive 5 -HT3 Antagonists (ondansetron 8 mg or equivalent) starting before the first dose 
of selinexor and continued bid – tid prn.   
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
30 5.18 Supportive Care Guidelines  for selinexor  
 
TABLE:  SUPPORTIVE CARE AND SELINEXOR DOSE ADJUSTMENT GUIDELINES FOR AES RELATED TO SELIN EXOR
A,B 
Toxicity and Intensity  Supportive Care and Dose Adjustment Guidelines  
Fatigue  
Grade 1  Maintain dose. Rule out other causes. If found to be anemic and 
symptomatic, consider transfusing even with hemoglobin >8 g/dL (anemia 
Grade <3).  
Patients with significant fatigue after several doses of selinexor may have 
an antitumor response. Consider an unscheduled assessment of tumor 
response as part of the patient’s evaluation.  
Grade  2 lasting  ≤7 days As per the NCCN guidelines, consider stim ulants such as methylphenidate 
5mg QD in the morning only.  
Grade 2 lasting >7 days or  
Grade ≥3  Rule out other causes. If found to be anemic and symptomatic, consider 
transfusions for hemoglobin >8 g/dL (Grade <3); transfusions usually 
indicated for Hb <8 g/dL (Grade ≥3). Interrupt selinexor dosing until 
resolved to Grade 1 or baseline.  
For first occurrence, restart selin exor at current dose.  
For ≥ second occurrence, reduce selinexor by 1 dose level.  
Patients with significant fatigue after several doses of selinexor may have 
an antitumor response. Consider an unscheduled assessment of tumor 
response as part of the patient’s evaluation.  
As per the NCCN guidelines, consider stimulants such as methylphenidate 
5mg QD in the morning only.  
Anorexia or Weight loss  
Grade 1 anorexia   Maintain dose. Rule out other causes. Consider nutritional consultation 
and use nutritional supplements (eg, Ensure®, Boost®). 
For persistent symptoms, start appetite stimulants, such as olanzapine (2.5 
to 5 mg PO every morning) or megesterol acetate (400 mg QD), per 
NCCN guidelines.  
Grade1 weight loss  
Grade 2 anorexia  Initiate appetite stimulants, such as olanzapine (2.5 to 5 mg PO every 
morning) or megesterol acetate (400  mg QD), as per NCCN guidelines.  
Grade 2 weight loss  
Grade 3 anorexia,  
or Grade 3 weight loss  Interrupt selinexor dosing until improved to Grade 1 o r baseline and weight 
stabilizes. Reduce selinexor by 1 dose level.  
Rule out other causes. Consider nutritional consultation and use  nutritional 
supplements (eg, Ensure®, Boost®)  
Start appetite stimulants as above,  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
31 Toxicity and Intensity  Supportive Care and Dose Adjustment Guidelines  
Nausea, Acute  
Grade 1 or 2  
 Maintain dose. Rule out other causes. U se standard  additional anti -nausea 
medication s to supplement the protocol -required 5 -HT3 antagonists.  
Use additional anti- nausea medications to supplement the protocol -
required 5 -HT3 antagonist(s). Olanzapine 2.5 to 5  mg PO every morning, 
per NCCN guidelines, can mitigate nausea and anorexia.  
Grade 3  Rule out other causes. U se additional anti -nausea med ication s to 
supplement the protocol -required 5 -HT3 antagonist(s). Olanzapine 2.5 to 
5 mg PO every morning, per NCCN guidelines, can mitigate nausea and 
anorexia.  
Interrupt selinexor dosing until resolved to Grade ≤2 or baseline and 
reduce selinexor by 1 dose level.  
Patients with significant nausea/vomiting after several doses of selinexor 
may have an antitumor response. Consider an unscheduled assessment of 
tumor response as part of the patient’s evaluation.  
Hyponatremia  
Grade 1 (sodium levels <  Normal to 
130 mmol/L)  Maintain dose. Rule out other causes including drug (eg, diuretic) effects.  
Be certain that reported sodium level is corrected for concurrent 
hyperglycemia (serum glucose >150 mg/dL).  
Treat hyponatremia per institutional guidelines including dietary review.   
Provide supplemental oral and/or intravenous fluids if dehydration is 
present. Conside r addition of salt tablets to patient’s diet.  
Grade 3 with sodium levels 
<130- 120 mmol/L without 
symptoms  Rule out other causes including drug (eg, diuretic) effects.  
Be certain that reported sodium level is corrected for concurrent 
hyperglycemia (serum glucose >150 mg/dL).  
If (corrected) sodium is Grade ≤3 and continues to be asymptomatic, then patient may continue current dosing without interruption provided that IV saline and/or salt tablets are provided and patient is followed closely.  
If Grade 3 is persistent or worsens or does not respond to treatment, interrupt selinexor dosing until resolved to Grade 1 or baseline and reduce 
selinexor by 1 dose level.  
Grade 3 with sodium levels 
<130- 120 mmol/L with symptoms 
or Grade 4 (<120 mmol/L)  Rule out other causes including drug (eg, diuretic) effects.  
Be certain that reported sodium level is corrected for concurrent hyperglycemia (serum glucose >  150 mg/dL).  
Interrupt s elinexor dosing until resolved to Grade 1 or baseline and 
without symptoms. Reduce selinexor by 1 dose level.  
Diarrhea  
Grade 1  Maintain dose. Rule out other causes including drug effects. Treat per 
institutional guidelines with anti -diarrheals , such as loperamide. 
Grade 2  Rule out other causes including drug effects. Treat per institutional 
guidelines with anti- diarrheals. Interrupt selinexor dosing until resolved to 
Grade 1 or baseline.  
For first occurrence, restart selinexor at current dose.  
For ≥ second occurrence, reduce selinexor by 1 dose level.  
Grade 3 or 4  Interrupt selinexor dosing until resolved to Grade 1 or baseline and patient 
is clinically stable. Reduce selinexor dose by 1 dose level.  
Thrombocytopenia  
Grade 1 or 2  Maintain dose. Rule out other causes including drug effects.  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
32 Toxicity and Intensity  Supportive Care and Dose Adjustment Guidelines  
Grade 3 without bleeding  Rule out other causes including drug effects.  
For first occurrence: skip 1 dose and reduce selinexor by 1 dose level.  
If recurrent, unless contraindicated, start treatment with moderate to high 
doses of thrombopoietin stimulating agents such as romiplostim 5 to 10 µg/kg SC weekly (preferred) or eltrombopag 100 to 150 mg QD.  
In cases where there is significant disease involvement  in the bone marrow 
or pre -existing compromised marrow function (eg, due to prior marrow -
toxic therapy),  or if there is baseline thrombocytopenia Grade 2- 4 at 
baseline, the Investigator in consultation with the Me dical Monitor may 
decide to continue selinexor dosing without dose reductions and/or 
interruptions as specified above, provided that platelet counts and bleeding 
symptoms/signs are closely monitored.
 Thrombopoietin stimulating agents 
are recommended.  
Grade 4 without bleeding  Rule out other causes including drug effects.  
Interrupt selinexor until patient recovers to Grade 2 or baseline. Selinexor 
dosing may be reduce d by 1 dose level  (it is recommended to have only 1 
dose modification per cycle).  
If recurrent, unless contraindicated, start treatment with moderate to high 
doses of thrombopoietin stimulating agents as above.  
In cases where there is significant disease involvement in the bone marrow  
or pre -existing compromised marrow function (eg, due to prior marrow -
toxic therapy), the Investigator in consultation with the Medical Monitor may decide to continue selinexor dosing without dose reductions and/or 
interruptions as specified above, provided that platelet counts and bleeding 
symptoms/signs are cl osely monitored.  
Grade ≥3 with  bleeding  
 Interrupt selinexor dosing and check platelet counts weekly until the bleeding has stopped, patient is clinically stable and the platelets have recovered to Grade 2 or baseline. When resuming selinexor, reduce by 
1 dose level.  
If recurrent, unless contraindicated, start treatment with moderate to high 
doses of thrombopoietin stimulating agents as above.  
Neutropenia  
Grade 3 or 4 neutropenia (afebrile)  
OR 
Febrile neutropenia  Institute colony stimulating factors and prophylactic antibiotics as 
clinically indicated per institutional guidelines.  
Interrupt selinexor and check neutrophils at least weekly until recovers to Grade  2 or baseline and without fever (if febrile) and the patient is 
clinically  stable. Reinitiate selinexor therapy and colony stimulating 
factors per institutional guidelines.  
If recurrent, continue colony stimulating factors, interrupt selinexor until neutrophil counts improve to Grade ≤2 or baseline levels, and reduce dose 
of selinexor 1 dose level.  
Anemia  
Treat per institutional guidelines including blood transfusions and/or erythropoietins. Consider transfusing for 
symptoms with hemoglobin  >8 g/dL (Grade <3) or for any Grade 3 (hemoglobin <8 g/dL). If possible, maintain 
selinexor dose as long as patient is clinically stable, but if a dose reduction or interruption is desired, consult with 
the Medical Monitor.  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
33 Toxicity and Intensity  Supportive Care and Dose Adjustment Guidelines  
Tumor lysis syndrome  
If TLS risk factors are identified, provide prophylactic IV hydration and regular monitoring of hydration 
(especially when increasing the dose of selinexor), renal function, urine output, and clinical laboratory measures 
of interest for TLS (eg, phosphorus, potassium, calcium, LDH, uric acid). Consider administration of hypouric emic agents to reduce the risk of TLS.  
Hold selinexor in patient with hyperkalemia (≥7.0 mmol/L) and/or symptoms of hyperkalemia, an increase in uric acid, or other changes in biochemical blood parameters suggestive of TLS. Start  IV hydration, and consider  
hypouricemic agent until levels return to normal. Selinexor can be reintroduced at the normal or reduced dose.  
Other selinexor -related adverse events  
Grade 1 or 2  Rule out other causes. Maintain dose. Start  treatment and/or standard 
supportive care per institutional guidelines.  
Grade 3 or 4  Rule out other causes. Interrupt selinexor until recovers to Grade 2 or 
baseline and reduce selinexor by 1 dose level.  
Isolated values of Grade ≥3 alkaline phosphatase do NOT require dose interruption. Determination of liver versus bone etiology should be made, 
and evaluation of gamma -glutamyl transferase, 5' -nucleotidase, or other 
liver enzymes should be performed.  
1. AFOR ALL  GRADE ≥3 HEMATOLOGIC  OR NON- HEMATOLOGIC 
AES  THAT ARE  NOT  SELINEXOR RELATED, AFTER CONSULTATION WITH THE 
MEDICAL MONITOR AND AT THE DISCRETION OF THE INVESTIGATOR, 
SELINEXOR DOSING MAY BE MAINTAINED.  
2. BFOR ALL SELINEXOR -RELATED AE’S, IF THE BELOW PRESCRIBED DOSE 
REDUCTIONS/INTERRUPTIONS RESULT IN A STABILIZATION OF ≥4 WEEKS, A RE-
ESCALATION MAY BE CONSIDERED AFTER APPROVAL FROM THE MEDICAL MONITOR.  
3. ALL DOSE MODIFICATIONS SHOULD BE BASED ON THE WORST PRECEDING TOXICITY.  
4. NOTE: WHEN TOXICITIES DUE TO SELINEXOR HAVE RETURNED TO BASELINE LEVELS OR THE PATIENT HAS STABILIZED, THE DOSE OF SELINEXOR MAY BE RE-ESCALATED IN CONSULTATION WITH THE MEDICAL MONITOR.  
 
5.19 Duration of Therapy 
 In the absence of treatment delays due to adverse event (s), treatment may continue indefinite ly 
or until one of the following criteria applies:  
• Disease progression,  
• Intercurrent illness that prevents further administration of treatment,  
• Unacceptable adverse event(s),  
• Patient decides to withdraw from the study, or 
• General or specific changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator. 
• Patients enrolled in Cohort 3 will discontinue therapy in a response-adapted manner.  All patients will discontinue selinexor afte r 14 cycles.  Patients who achieve a MRD 
negative CR at 14 cycles will discontinue both selinexor and ibrutinib.  Patients who achieve a MRD – PR will discontinue both selinexor and ibrutinib at discretion of treating physician.  Patients with any other response are recommended to continue ibrutinib indefinitely.  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
34   5.20 Duration of Follow Up 
 Patients will be followed every 6 months until progression or an alternative therapy is started.  Patients removed from study for unacceptable adverse event(s) will be followed until resolution or stabilization of the adverse event.  Follow-up data will be required unless consent is withdrawn.  5.21 Criteria for Removal from Treatment  
 At the discretion of the Investigator, the investigator may remove a patient from the study treatment for the following reasons:  
 
• Death,  
• Disease progression,  
• Noncompliance with study procedures, 
• Intercurrent illness that prevents further administration of treatment,  
• Need of treatment with medications not allowed by the study protocol, 
• Unacceptable adverse event(s),  
• Other treatments become available , 
• Treatment delays exceeding 28 days, 
• Patient decides to withdraw from the study, or 
• General or specific changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator.  
 The reason for study removal and the date the patient was removed must be documented in the Case Report Form.   Patients who are removed from protocol therapy will still be followed for 
progression and survival.  6. DOSING DELAYS/DOSE MODIFICATIONS  
 Toxicities that occur in cycle 1 t hat are DLTs (Section 4 .2) will result in protocol removal. 
Adverse events that are not defined as DLTs and / or occur in cycles 2 and higher will lead to 
dose delays and modifications as detailed below. No dose reduction below ibrutinib 140 mg and selinexor 20 mg/week  will be allowed. If a patient experiences several adverse events, and there 
are conflicting recommendations, the investigator should use the recommended dose adjustment that reduces the dose to the lowest level. Missed doses will not be replaced. Treatment delays for adverse events exceeding 28 days will lead to protocol removal unless approved by the principal investigator.  Ibrutinib -related lymphocytosis, for the purposes of this protocol, is defined as an elevation in 
blood lymphocyte count of ≥50% compared with baseline count in conjunction with unequivocal improvement in at least 1 other disease -related parameter including lymph node size, spleen size, 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
35 hematologic parameters (hemoglo bin or platelets), or disease-related symptoms. Ibrutinib-
associated treatment -related lymphocytosis generally occurs within the first few weeks of 
therapy, peaks within the first few months, and resolves slowly.  Patients with isolated lymphocytosis in the setting of reduced disease burden or improvement in hemoglobin/platelets should not be considered to have progressive disease.  Asymptomatic treatment-related lymphocytosis should not be considered an adverse event. Subjects with treatment-related lymphocytosis in the absence of other disease-related symptoms should be encouraged to remain on study treatment and continue with all study- related 
procedures.   6.1 Dose adjustment guidelines for hematologic ibrutinib or selinexor -related t oxicities  
 
Toxicities that are clearly not related to ibrutinib or selinexor will not require a dosing modification.  Similarly, toxicities that are clearly attributable to an individual drug will only require modification of that drug, with modifications following the tables below.  
  
Event Name  Neutropenia , Anemia, or Thrombocytopenia  
For Patients with Baseline Absolute Neutrophil Count ≥ 1000/mm3; 
Hemoglobin ≥ 11g/dL; or Platelets ≥ 100,000/mm3 
Grade of 
Event  Management/Next Dose Ibrutinib* Management/Next Dose of Selinexor* 
< Grade 3  No change in dose  No change in dose  
≥ Grade 3  Hold until neutrophils, hemoglobin, 
or platelets have returned to < Grade 
3.   
• 1st occurrence: No change in dose 
• 2nd occurrence: Cohort 1 and 3= N o 
change in dose; Cohort 2 = Decrease ibrutinib to next lowest dose level  
• 3
rd occurrence: Decrease ibrutinib 
to next lowest dose level 
• 4th occurrence: Patient comes off 
study  Hold until neutrophils, hemoglobin , or 
platelets  have returned to < Grade 3 . 
• 1st occurrence: No change in dose 
• 2nd occurrence: Decrease selinexor to 
next lowest dose. 
• 3rd occurrence: No change in dose 
• 4th occurrence: Patient comes off 
study 
*Dose reductions < ibrutinib 140mg daily or selinexor 20 mg  weekly are not permitted.  
Recommendations:   
-Full supportive care, growth factors, and transfusions should be given as medically indicated. 
- If the patient tolerates a reduced dose for two cycles, patient may be dose escalated to the 
dose they received prior to the reduction after authorization from Principal Investigator.  
 
Event Name  Neutropenia , Anemia , or Thrombocytopenia  
For Patients with Baseline Absolute Neutrophil Count ≤ 1000/mm3; 
Hemogl obin ≤ 11g/dL; or Platelets ≤ 100,000/mm3 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
36 Grade of AE  Management/Next Dose Ibrutinib* Management/Next Dose of Selinexor* 
<Grade 3  No change in dose  No change in dose  
≥ Grade 3  Hold until neutrophils, hemoglobin , 
or platelets  have returned to within 
50% of pretreatment values .  If 
initial value is within 50% of 
pretreatment value, no hold is 
needed.  
• 1st occurrence: No change in dose 
• 2nd occurrence: Cohort 1 and 3= 
No change in dose; Cohort 2  = Decrease ibrutinib to the next lowest dose level.  
• 3
rd occurrence: Decrease ibrutinib 
to the next lowest dose level. 
• 4th occurrence: Patient comes off 
study Hold until neutrophils, hemoglobin , or 
platelets  have returned to within 50% 
of pretreatment valu es.  If initial value 
is within 50% of pretreatment value, 
no hold is needed. 
 
• 1st occurrence: No change in dose.  
Initiate granulocyte colony-stimulating factors for grade >3 neutropenia. 
• 2
nd occurrence: Decrease selinexor to 
next lowest dose. 
• 3rd occurrence: No change in dose 
• 4th occurrence: Decrease selinexor to 
the next lowest dose 
• 5th occurrence:  No change in dose 
• 6th occurrence: Discontinue selinexor  
*Dose reductions < ibrutinib 140mg daily or selinexor 20 mg weekly are not permitted.  
Recommendations:   
-Full supportive care, growth factors, and transfusions should be given as medically indicated. 
- If the patient tolerates a reduced dose for two cycles, patient may be dose escalated to the 
dose they received prior to the reduction after authorization from Principal Investigator.  
 
Event Name  Bleeding  
Grade of 
Event  Management/Next Dose Ibrutinib* Management/Next Dose of Selinexor* 
≤ Grade 2  
(mild to 
moderate)  Hold ibrutinib for at least 7 days 
after last bleeding and until platelets return to ≥ 50% of baseline value.  
• 1st occurrence: Restart ibrutinib at 
next lowest dose level.  In cases 
where no bleeding is observed after 6 days of dosing return to full dose at the physician’s discretion.    
• 2
nd occurrence: Restart ibrutinib at 
next lowest dose level. 
• 3rd occurrence: Patient comes off 
study.  Hold selinexor for at least 7 days after 
last bleeding and until platelets return to ≥ 50% of baseline value.  
• 1st occurrence: Restart selinexor at  
next lowest dose level. In cases 
where no bleeding is observed after 6 days of dosing return to full dose at the physician’s discretion.    
• 2
nd occurrence: Restart selinexor at 
next lowest dose level.   
• 3rd occurrence: Patient comes off 
study.  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
37 ≥ Grade 3  
(severe)  
 Hold ibrutinib for at least 7 days 
after last bleeding and until platelets return to ≥ 50% of base line value.  
• 1st occurrence: Restart ibrutinib at 
next lowest dose level.   
• 2nd occurrence: Patient comes off 
study.  Hold selinexor for at least 7 days after 
last bleeding and until platelets return to ≥ 50% of baseline value.  
• 1st occurrence: Restart sel inexor at 
next lowest dose level.   
• 2nd occurrence:  Patient comes off 
study.  
*Dose reductions < ibrutinib 140mg daily or selinexor 20 mg weekly are not permitted . 
Recommendations:   
-Full supportive care, growth factors, and transfusions should b e given as medically indicated.  
  
Event Name  Neutropenic Fever  
Grade of 
Event  Management/Next Dose Ibrutinib* Management/Next Dose of Selinexor* 
Grade 3  
 Hold until toxicity ≤ Grade 2 or 
baseline.   
• 1st occurrence: No change in dose. 
• 2nd occurrence: Decrease ibrutinib 
to next lowest dose level. 
• 3rd occurrence:  Patient comes off 
study . Hold until toxicity ≤ Grade 2 or 
baseline.  
• 1st occurrence: Decrease selinexor to 
next lowest dose. 
• 2nd occurrence: No change in dose.  
• 3rd occurrence:  Patient comes off 
study . 
Grade 4  
 Hold until toxicity ≤ Grade 2 or 
baseline.   
• 1st occurrence: Decrease ibrutinib 
to next lowest dose level. 
• 2nd occurrence: Decrease ibrutinib 
to next lowest dose level. 
• 3rd occurrence:  Patient comes off 
study  Hold until toxicity ≤ Grade 2 or 
baseline.  
• 1st occurrence: Decrease selinexor to 
next lowest dose. 
• 2nd occurrence: Decrease selinexor to 
next lowest dose level. 
• 3rd occurrence:  Patient comes off 
study  
*Dose reductions < ibrutinib 140mg daily or selinexor 20 mg  weekly are not permitted.  
Recommendations: 
-Full supportive care and/or grow th factors should b e given as medically indicated.  
 6.2 Dose adjustment guidelines for non-hematologic ibrutinib or selinexor- related 
toxicities  
 Specific guidelines are provided below for non-hematologic toxicities. For all other grade 3 non-hematologic toxicities possibly related to study therapy, hold the causative agent, or if the causative agent cannot be determined, hold both ibrutinib and sel inexor. Once the toxicity is 
improved to ≤ Grade 2 or until baseline pre -treatment value, resume treatment with a decrease in 
the dose of ibrutinib by 140 mg or selinexor by one dose level. No dose reduction below ibrutinib 140 mg and selinexor 20 mg/week will be allowed. If a patient experiences several 
adverse events, and there are conflicting recommendations, the investigator should use the 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
38 recommended dose adjustment that reduces the dose to the lowest level. Missed doses will not be replaced. Treatment  delays for adverse events exceeding 28 days will lead to protocol removal.  
 Any Grade 4 toxicities (lasting ≥7 days for transaminase or electrolyte abnormalities) that are at least possibly attributed to selinexor or ibrutinib should result in permanent discontinuation of the causative agent.  If attribution to a single drug cannot be made, both drugs should be discontinued.  
Event Name  Nausea  
Grade of 
Event  Management/Next Dose Ibrutinib  Management/Next Dose of Selinexor  
Grade 1  No change in dose  5-HT3-antagonists, D2 -antagonists or 
NK1 antagonists, or dronabinol or 
combinations can prevent nausea in 
the majority of patients.  Consider 
additional anti- emetics (see the NCCN 
Clinical Practice Guideline for  
antiemesis ). Provide guidance on diet 
as described above for anorexia as 
increased caloric intake may reduce 
nausea.  
Grade 2  No change in dose  Implement one or more combinations 
of anti- nausea medications.  Consider 
additional anti- emetics (see the NCCN 
Clinical Practice Guideline for 
antiemesis).   If Grade 2 nausea 
persists, reduce dose of selinexor by 
one dose level.  If patient’s nausea is 
Grade ≤1 for 4 weeks, then the dose of 
selinexor may be increased back to the 
previous dose level.  
Grade 3  No change in dose  Interrupt dosing of selinexor and 
implement one or more combinations 
of anti- nausea medications.   Consider 
additional anti- emetics (see the NCCN 
Clinical Practice Guideline for 
antiemesis).   Ensure adequate caloric 
and fluid intake.  Restart selinexor 
with one dose level reduction when 
nausea is Grade ≤  2 and adequate 
caloric and fluid intake have been 
achieved. If patient’s nausea is Grade 
≤1 for 4 weeks, then the dose of 
selinexor may be increased back to the 
previous dose level.  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
39 Recommendations:   
-Full supportive care and antiemetics.  See Section 4.4.  
- If the patient tolerates a reduced dose for two cycles, patient may be dose escalated to the 
dose they received prior to the reduction after authorization from Principal Investigator.  
 
Event Name  Vomiting  
Grade of 
Event  Management/Next Dose Ibrutinib  Management/Next Dose of Selinexor  
≤ Grade 2  No change in dose  No change in dose  
Grade 3  No change in dose  Hold until toxicity ≤ Grade 1.  
Decrease by one dose level.   
Recommendations:   
-Full supportive care and antiemetics.  See Section 4.4.  
 
Event Name  Diarrhea  
Grade of 
Event  Management/Next Dose Ibrutinib  Management/Next Dose of Selinexor  
Grade 1  No change in dose  Rule out other causes of diarrhea, 
including infectious agents. At the first 
sign of abdominal cramping, loose 
stools, or onset of diarrhea, it is 
recommended that the patient be 
treated according to institutional 
standard of care, e.g., lop eramide 
(Immodium®).  Maintain dose level of 
selinexor.  
Grade 2  No change in dose  If diarrhea is present despite maximal 
anti-diarrheal medication, rule out 
other causes of diarrhea, including 
infectious agents. Reduce selinexor by 
one dose level until resolved to 
≤ Grade 1, then re- start at the current 
dose level.  
If diarrhea returns as Grade ≥  2, then 
reduce selinexor dose by one dose 
level.  If patient is stable and diarrhea 
resolves (Grade 0 or baseline with or 
without anti- diarrheals) for 4 weeks, 
then the patient’s dose may be re-
escalated  
Grade 3   Hold until ≤ Grade 1.  Decrease 
ibrutinib to next lowest dose level. If diarrhea is present despite maximal 
anti-diarrheal medication , rule out 
other causes of diarrhea, including 
infectious agen ts. Delay selinexor until 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
40 resolved to Grade ≤2, then reinitiate 
selinexor at one dose level below. If 
patient is stable and diarrhea resolves 
(Grade 0 or baseline with or without 
anti-diarrheals) for 4 weeks, then the 
patient’s dose may be re -escalated.  
Recommendations:   
-Full supportive care and antidiarrheal agents.  See Section 4.4.  
 
Event Name  Fatigue  
Grade of 
Event  Management/Next Dose Ibrutinib  Management/Next Dose of Selinexor  
Grade 1  No change in dose  Ensure adequate caloric intake and 
assess volume status.  Recommend 
high calorie and/or energy drinks 
and/or foods.  Adjust other 
medications.  Rule out other causes of 
fatigue such as adrenal insufficiency, 
hypothyroidism, etc.  
Grade 2  No change in dose  Ensure adequate caloric and fluid 
intake and assess volume status.  Add 
supportive care for fatigue, or reduce 
the dose of selinexor by one level.  If 
patient’s fatigue is Grade ≤1 for 4 
weeks, then the dose of selinexor may 
be increased back to the previous dose 
level.  
Grade 3  No change in dose  Ensure adequate caloric and fluid 
intake and assess volume 
status.   Interrupt selinexor dosing until 
resolved to Grade ≤  2, reduce dose of 
selinexor by 1 level. If patient’s 
fatigue is Grade ≤1 for 4 weeks, then 
the dose of selinexor may be increased 
back to the previous dose level.  
Recommendations:   
- Optimize supportive care including caloric and fluid intake.  Add glucocorticoids when not 
contra -indicated.  See Section 4.4.  
 
Event Name  Rash  - Maculopapular  
Grade of 
Event  Management/Next Dose Ibrutinib* Management/Next Dose of Selinexor* 
≤ Grade 1  No change in dose  No change in dose  
Grade 2  Hold until ≤ Grade 1.  Resume same 
dose.  No change in dose  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
41 Grade 3  Hold until toxicity ≤ Grade 1.   
• 1st occurrence: Decrease ibrutinib 
to next lowest dose level. 
• 2nd occurrence: Decrease ibrutinib 
to next lowest dose level. Hold until toxicity ≤ Grade 1 or 
baseline.  
• 1st occurrence: No change in dose.  
• 2nd occurrence: Decrease selinexor to 
next lowest dose l evel.  
*Dose reductions < ibrutinib 140 mg daily or selinexor 20 mg  weekly are not permitted.  
Recommendations:   
- Review medication list and discontinue any medications that commonly cause rash if 
possible. 
-Consider skin biopsy.  
 
Event Name  Thrombosis/Thromboembolic Event  
Grade of 
Event  Management/Next Dose Ibrutinib  Management/Next Dose of Selinexor  
≤ Grade 1  No change in dose  No change in dose  
Grade 2 or 3  Hold until therapeutically 
anticoagulated and platelets are ≥ 
50,000/mm3. Resume at the same 
dose level.   Hold until therapeutically 
anticoagulated and platelets are ≥ 
50,000/mm3. Resume at the same dose 
level.   
Recommendation: Anticoagulation  (warfarin prohibited)  
 
Event Name  Hyponatremia  
Grade of 
Event  Management/Next Dose Ibrutinib  Management/Next Dose of Selinexor  
Grade 1 
(Lower Limit of Normal to 130 nM) No change in dose Maintain selinexor dose and frequency 
level, assure adequate fluid, electrolyte 
and caloric intake, adjust other 
medications, and consider salt 
supplementation 1- 3 times per 
day. Correct sodium level for 
hyperglycemia (serum glucose 
>150 mg/dL).  Rule out other causes 
of low sodium (e.g., SIADH, cardiac, 
hepatic, adrenal, renal, and thyroid 
diseases, Fanconi Syndrome, diuretic 
use, e tc.). 
Grade  3 (126 -
129 mmol/L )  No change in dose  Ensure patient is euvolemic and has 
sufficient fluid and electrolyte 
intake.   Replace fluids orally or IV if 
patient is dehydrated.  Correct sodium 
level for hyperglycemia.  Rule out 
other causes of low sodium (see above 
for Grade 1).  
Hold selinexor until hyponatremia 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
42 resolves to Grade ≤1 (≥130 nM) and 
initiate aggressive salt 
supplementation 2- 3 times per 
day.  Restart at the same dose and 
frequency of selinexor and monitor 
serum sodium closely.  If this  recurs, 
measure urine sodium and creatinine 
levels to investigate for other causes of 
hyponatremia.  
Grade 3 (120 -
125 mmol/L ) No change in dose  Hold selinexor dose until sodium ≥ 
125 mmol/L*.  Decrease selinexor to 
the next lowest dose level for initial 
and each subsequent occurrence.  
*If sodium does not recover to ≥ 125 mmol/L  within 14 days of holding selinexor, selinexor 
should be permanently discontinued 
• In marked hyperglycemia, ECF osmolality rises and exceeds that of ICF, since glucose 
penetrates cell membranes slowly in the absence of insulin, resulting in movement of water 
out of cells into the ECF. Serum Na concentration falls in proportion to the dilution of the 
ECF, declining 1.6 mEq/ L for every 100 mg/dL (5.55 mmol/L) increment in the plasma 
glucose level above normal. This condition has been called translational hyponatremia 
because no net change in total body water (TBW) has occurred. No specific therapy is 
indicated, because Na concentration will return to normal once the plasma glucose concentration is lowered. Corrected Sodium = Measured sodium + 0.024 * (Serum 
glucose - 100).  
 
Event Name  Anorexia  
Grade of 
Event  Management/Next Dose Selinexor  
Grade 1   Assess dietary options (e.g., try a 
variety of other foods).  Add high-
calorie supplements (e.g., Ensure®). 
Consider an appetite stimulant(s) (see 
the NCCN Clinical Practice Guideline 
for anorexia).  
Grade 2   Add hi gh-calorie supplements (e.g., 
Ensure®).  Add an appetite stimulant(s) 
(see the NCCN Clinical Practice 
Guideline for anorexia).  Selinexor 
dosing may be interrupted 
intermittently while supportive 
medications are instituted, usually for 
<1 week.  If Grade 2  anorexia does not 
resolve after institution of supportive 
medications, reduce selinexor dose by 
1 level .  If patient’s anorexia is Grade 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
43 ≤1 for 4 weeks, then the dose of 
selinexor may be increased back to the 
previous dose level.  
Grade 3   Interrupt dosi ng with selinexor until 
resolution to Grade ≤2.  Add high 
calorie supplements.  As described 
above, initiate supportive medications 
for anorexia.  Restart selinexor at 1 
dose level reduction .  once anorexia 
resolves to Grade ≤  2 and follow the 
guidelines above. If patient’s anorexia 
is Grade ≤1 for 4 weeks, then the dose 
of selinexor may be increased back to 
the previous dose level.  
 
 
Event Name  Weight Loss  
Grade of 
Event   Management/Next Dose of Selinexor  
Grade 1    Assess dietary options (e.g. try a  
variety of other foods). Add high-
calorie supplements (e.g., Ensure®). If 
fatigue or nausea also present, consider 
corticosteroids on day of and day after 
selinexor dosing. Consider an appetite 
stimulant(s) ( see the NCCN Clinical  
Practice Guideline for anorexia and 
anti-emesis).  
Grade 2  Add high -calorie supplements (e.g., 
Ensure®).  Consider corticosteroids on 
day of and day after s elinexor  dosing. 
Consider an appetite stimulant(s) (see 
the NCCN Clinical Practice  Guideline 
for anorexia and anti- emesis) .  
Consider megesterol acetate 80-400mg 
daily. Consider anabolic steroids such 
as oxandrolone. Consider dronabinol 
(Marinol®). If Grade 2 weight loss 
does not resolve after institution of 
supportive medications, reduce 
selinexor  dose by 1 level.  
Grade 3  Interrupt dosing with selinexor .  Add 
high calorie supplements.  Use 
supportive medications from above 
alone or in combinations.  Restart 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
44 selinexor  at 1 dose level reduction 
once weight loss resolves to Grade ≤2.  
If Grade 2 weight loss persists with 
supportive medications, reduce dose of 
selinexor by 2 levels. If patient’s 
weight loss is Grade ≤1 for 4 weeks, 
then the dose of selinexor may be 
increased back to the previous dose 
level.  
 
Event Name  Hypertension  
Grade of 
Event  Management/Next Dose Ibrutinib  Management/Next Dose of Selinexor  
Grade 1  No change in dose  No change in dose  
Grade 2  No change in dose  No change in dose  
Grade 3   No change in dose if hypertension 
is medically managed.  No change in dose  
Grade 4  If possibly, probably, or definitely 
related to ibrutinib, consider holding 
dose until hypertension improves to 
baseline with medical management 
of hypertension.  Ibrutinib can then 
be reinsituted at the same dose at 
first occurrence.  At second 
occurrence, r educe dose to 280 mg 
daily.  No change in dose  
  6.3 Dose Reduction for Decreased Glomerular Filtration Rate (GFR)  
 
Selinexor is not significantly eliminated by the kidney; therefore, no dose alteration of selinexor 
is required with renal dysfunction.  If dia lysis is implemented during selinexor treatment, then 
selinexor should always be given after dialysis.  Selinexor tablets are to be taken with at least 
120 mL (4 ounces) of fluids (water, juice, etc.) at approximately the same time each day.  
 
6.4 Dose Adjustment for Infection  
 Patients with active uncontrolled serious or suspected serious infections (i.e. Grade 3 or higher, or Grade 2 or higher at the discretion of the treating physician) should have selinexor and ibrutinib  treatment withheld until infection ha s clinically resolved or stabilized. Dexamethasone 
should be adjusted per institutional guidelines, and adrenal suppression considered.  After the infection has resolved clinically, or the patient’s clinical condition has stabilized, treatment with selinex or may continue at the original dose.  Missed doses will not be replaced.  Patients may 
continue on antibiotics or other anti-microbial agents for prolonged periods while re- initiating 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
45 their selinexor regimen at the discretion of the investigator.  Note: s elinexor has not been 
associated with opportunistic infections in approximately 400 patients treated as of 1 August 2014.  6.5 Conditions not Requiring Dose Reduction 
 The following conditions are exceptions to the above guidelines. selinexor does not need to be held in the following cases:  
• Alopecia of any grade  
• Electrolytes abnormalities that are reversible with standard interventions  
 6.6 Missed or Vomited Doses  
 Seline xor missed doses- If the dose was missed for more than 48 hours, the dose will be skipped 
and the next dose will be taken as per schedule. If the dose was missed within 48 hours, then it will be replaced.  
 If
 a patient missed a full week of dosing for non-study drug related events (eg. a required 
medical procedure or an unanticipated personal emergency), the days missed will not be replaced. For example, if patient missed C2D7 to C2D14, then patient will start on C2D15.  Ibrutinib missed doses- If
  a dose i s missed, it can be taken up to 6 hours after the scheduled time 
with a return to the normal schedule the following day. If it has been greater than 6 hours, the dose should not be taken and the subject should take the next dose at the scheduled time the next day. The missed dose will not be made up and must be reported  at the next scheduled visit. 
 Selinexor or ibrutinib vomited doses- If a dose is vomited within one hour of ingestion, it will be 
replaced. If vomiting occurs more than 1 hour after dosing, it will still be considered a complete dose.   6.7 D
elays, Modifications and Reintroduction 
 
All delays, modifications, and reintroductions of selinexor or ibrutinib dosing will be made in 
consultation with the principal investigator.  
 
7. ADVERSE EVENTS  (AES) :  LIST AND REPORTING REQUIREMENTS  
 All patients must be carefully monitored for AEs, including clinical laboratory tests.  AEs should be assessed in terms of their seriousness, intensity, and relationship to the study drug.  For consistency, events are to be graded using the CTCAE version 4.0.  A copy of the CTCAE version 4.0 can be downloaded from the CTEP web site http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm .   
 If CTCAE criterion does not exist for a particular AE, the investigator should use the grade or adjectives as  described below:  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
46 • Grade 1=Mild=Does not interfere with patient’s usual function 
• Grade 2=Moderate=Interferes to some extent with patient’s usual function  
• Grade 3=Severe=Interferes significantly with patient’s usual function  
• Grade 4=Life -Threatening=Results in a threat to life or in an incapacitating disability.  
 7.1 Definition of an Adverse Event  
 Adverse event (AE): Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and  which does not necessarily have to have a 
causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use o f study treatment, whether or not considered related to the study 
treatment. 
 
 7.2 Recording of Adverse Events  
 All AE will be reported and recorded from the time of the first dose of study drug through 30 
days after the last dose of study drug or until the start of subsequent antineoplastic therapy, 
whichever occurs first.  That is, if a patient begins a new antineoplastic therapy, the AE reporting period for nonserious AEs ends at the time the new treatment is started. AE monitoring should be continued for at least 30 days following the last dose of study treatment (i.e., through 30 days following last dose or until resolution or through the end of the study for events considered related to study treatment by the Investigator). AEs (including laboratory abnormalities that constitute AEs) should be described using a diagnosis whenever possible, rather than individual underlying signs and symptoms. When a clear diagnosis cannot be identified, each sign or symptom should be recorded as a separate AE.  The Investigator should ask the patient non-leading questions to determine if AEs occur during the study. AEs may also be recorded when they are volunteered by the patient, or through physical examination, laboratory tests, or other clinical assessments.  An AE should be followed until its resolution or until it is judged to be permanent, and assessment should be made at each visit (or more frequently, if necessary) of any changes in severity of the event, the suspected relationship to the study treatment, the interventions required to treat the event, and the outcome.  7.3 Laboratory Test Abnormalities 
 Laboratory abnormalities that constitute an AE in their own right (i.e., are considered to be clinically significant, induce clinical signs or symptoms, require concomitant therapy, or require changes in study treatment), should be recorded as an AE. Whenever possible, a diagnosis rather than a symptom should be recorded (e.g., anemia instead of low hemoglobin). Laboratory abnormalities that meet the criteria for an AE should be followed until they have returned to normal or an adequate explanation of the abnormality is identified. When an abnormal laboratory or test result corresponds to a sign/symptom of an already reported AE, it is not necessary to 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
47 separately record the laboratory/test result as an additional event.  A laboratory abnormality that does not meet the definition of an AE should not be recorded as an AE. A laboratory abnormality that results in a dose being held or modified would, by definition, be an AE. A Grade 3 or 4 event (severity per the current version of NCI CTCAE) does not automatical ly indicate an SAE unless it meets the definition of serious as defined in Section 5.11 
and/or as per the Investigator’s discretion.  
 
7.4 Adverse Events of Special Interest  
 AESIs for selinexor include cataracts and acute cerebellar syndrome. All cases of cerebellar toxicity, Grade 3 or higher must be reported.  
All cases of Grade 3 or higher cerebellar toxicities occurring in patients enrolled in the study from the 
informed consent signature and up to 30 days after the last drug administration , or after if related to study 
drug, must be immediately reported as SAE (even if not meeting the definition of a SAE) to the 
Sponsor by the investigator within 24 hours of first knowledge of the event by study personnel , using 
the SAE form provided by the Sponsor (fol low reporting rules for SAE in section 13.3).  
Reporting of Cataracts  
Sponsor is closely monitoring the occurrence of cataracts during treatment w ith selinexor as adverse 
events of special interest. Ophthalmic examinations are planned on regular basis to identify cataracts or 
worsening of existing cataracts. Any cataracts or worsening of existing cataracts has to be reported as an 
AE irrespectively of grade. 
 
  7.5 Adverse Event Severity Assessments  
 The severity* of the AE should be graded by the Investigator according to the NCI CTCAE Grading Scale, utilizing a current version of NCI CTCAE.  NCI CTCAE files can be accessed online at the following URL: http://evs.nci.nih.gov/ftp1/CTCAE/About.html ). 
• If NCI CTCAE grading does not exist for an AE, the severity should be characterized as 
‘mild,’ ‘moderate,’ ‘severe,’ ‘life -threatening’, or ‘fatal’ (corresponding to Grades 1 to 5) 
according to the following definitions: 
• Mild events are usually transient and do not interfere with the patient’s daily activities.  
• Moderate events introduce a low level of inconvenience or concern to the patient and 
may interfere with daily activities.  
• Severe events interrupt the patient’s usual daily activities.  
• Life-threatening  
• Fatal event.  
*Severity ≠ Seriousness:   The term ‘severe’ is used to describe the intensity of an AE; the event 
itself could be of relatively minor clinical significance (e.g., ‘severe’ headache). This is not the same as a ‘serious’ AE.   Grades do not define seriousness. 
 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
48 7.6 Adverse Event Causality  
 The Investigator will make a judgment regarding the relationship of the AE to study treatment, as outlined in Table 1. Table 1:         Classific ation of Adverse Events by Causality 
Not related The lack of a temporal relationship  of the event to the study 
treatment makes a causal relationship not reasonably possible, or 
other drugs, therapeutic interventions, or underlying conditions 
    Related The temporal relationship of the event to the study treatment 
makes a definitive relationship, and the event is more likely explained by exposure to the study treatment than by any other 
drugs, therapeutic interventions, or und erlying conditions.  
  7.7 Adverse Event Reporting  
 The Investigator will report all AEs (including all non -serious AEs) to Karyopharm 
Pharmacovigilance twice per year  in the form of line- listings. Karyopharm will supply the cut-
off dates.  The line listings will contain the following information:  study ID, unique subject ID, 
adverse event term, serious event (yes or no), onset date (complete or partial), end date (complete or partial), action taken with selinexor, causality to selinexor, event ongoing (yes or no), outcome of AE, severity CTCAE Grade (1-5), subject dosed with selinexor (yes or no), date of first dose of selinexor, preferred term (optional, system organ class (optional)  7.8 Serious Adverse Events  
 An AE is considered an SAE if at least one of the following conditions applies: 
 
• Death was an outcome of an adverse event;  
• Life threatening AE (i.e., an event in which the patient was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe);  
• Requires inpatient hospitalization or prolongation of existing hospitalization; 
• Emergency room visits that do not result in admission to the hospital should be evaluated for one of the other serious outcomes (e.g., life -threatening; required intervention to 
prevent permanent impairment or damage; other serious medically important event);  
• Results in persistent or significant disability/incapacity;  
• Is a congenital anomaly/birth defect;  
• A new cancer diagnosed during the study (histopathologically different from the cancer 
under study; and  
Any important medical events that may not result in death, are not life-threatening, or do not 
require hospitalization may be considered SAEs when, based on appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent 1 of 
the outcomes listed in this definition. Examples of such events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in in-patient hospitalization, or the development of drug dependency or drug 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
49 abuse. Hospitalizations for elective surgery or other medical procedures that are not due to an AE are not considered SAEs. A hospitalization meeting the regulatory definition for ‘serious’ is any inpatient hospital admission that includes a minimum of an overnight stay in a health care facility. An emergency room visit is not considered a hospital ization unless it results in an 
official admission to the hospital.  
 Progression of the malignancy (including fatal outcomes) should not be reported as an SAE during the study or within the safety reporting period. Sudden and unexplained death should be reported as an SAE. If there is any uncertainty about a finding being due solely to progression of 
malignancy, the finding should be reported as an AE or SAE, as appropriate.  7.9 Recording of Serious Adverse Events  
 Per the Good Clinical Practices, it is recommended that Investigator has the responsibility to record and document all SAEs occurring from the signing of the Informed Consent Form until at least 30 days after the patient has stopped study treatment.  7.10 Reporting of Serious Adverse Events  
 Every SAE, regardless of the causal relationship to the Karyopharm medications, occurring after the patient has signed informed consent until 30 days after the patient has stopped study treatment must be reported to the Karyopharm Pharmacovigilance within 24 hours of a wareness. 
A Karyopharm SAE Report Form template is provided for this purpose (Appendix D ). For 
reporting any SAE to Karyopharm Pharmacovigilance Department, a completed and signed (by the Investigator) SAE Report Form will be submitted to Karyopharm Pharma covigilance:  
 Completed and signed SAE report forms must be emailed or faxed to:  
Pharmacovigilance Department  
Karyopharm Therapeutics Inc. Email: pharmacovigilance@karyopharm.com Fax:     +1 -617-334-7617 (USA) 
 Any SAE observed after the 30-day follow-up period should only be reported to Karyopharm if the Investigator suspects that the SAE has causal relationship to study treatment.   An SAE should be followed until its resolution or until it is judged to be permanent, and assessment should be made at each  visit (or more frequently, if necessary) of any changes in 
severity of the event, the suspected relationship to the study treatment, the interventions required to treat the event, and the outcome.  New information, recurrences, complications, or progression of the initial SAE must be reported as follow -up to the initial report within 24 hours of the 
Investigator receiving the follow-up information.  Investigators are responsible as applicable for notifying their appropriate Health Authorities, Institutional Review Board or Local and Central Ethics Committees (EC) of all SAEs in 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
50 accordance with local regulations.   Karyopharm Therapeutics will report applicable SAEs to other applicable Regulatory Agencies and Investigators utilizing the Karyopharm product, as may be required.  7.11 Suspected Unexpected Serious Adverse Reactions  
 Suspected unexpected serious adverse reactions (SUSARs) are SAEs that are unexpected and judged by the Investigator or Karyopharm to be related to the study treatment administered.   SUSARs will be collected and reported to the competent authorities and relevant ethics committees in accordance with the FDA’s ‘Safety Reporting Requirements for Investigational New Drugs and Bioanalytical/Bioequivalence Studies’ or as per national re gulatory requirements 
in participating countries.  7.12 Procedures for Handling Special Situations  
 
7.12.1 Pregnancy  
 Note: Pregnancy per se is not considered to be an AE; however, it is discussed here because of the importance of reporting pregnancies that occur during studies and because a medical occurrence observed in the mother or fetus/newborn would be classified as an AE.  
 To ensure patient safety, a pregnancy occurring while the patient is on study treatment must be reported to Karyopharm Pharmacovigilance by email or fax within 24 hours of first knowledge of its occurrence. A pregnancy report form is provided Karyopharm Therapeutics Inc.   The pregnancy should be followed up to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications.  A pregnancy in a female partner of a male patient must be reported to Karyopharm within 24 hours of learning of its occurrence.   Pregnancies must be reported to Karyopharm, regardless of whether the patient withdraws from the study or the study is completed, for 3 months after the patient receives his/her last dose of study treatment. Patients should be instructed to inform the investigator regarding any pregnancies.   Any SAE that occurs during pregnancy must be recorded on the SAE report form (e.g., maternal serious complications, therapeutic abortion, ectopic pregnancy, stillbirth, neonatal death, congenital anomaly, birth defect) and reported within 24 hours in accordance with the procedure for reporting SAEs.  
 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
51 7.13 Abuse, Misuse, Medication Errors, Overdose, and Occupational Exposure 
 All incidences of abuse, misuse, medication errors, overdose, and occupational exposure are required to be reported to Karyopharm pharmacovigilance on an SAE report form emailed to pharmacovigilance@karyopharm.com, regardless of whether or not there is an associated AE or SAE.    
7.13.1 Overdose 
 An overdose is a deliberate or accidental administration of any Karyopharm treatment to a study patient, at a dose greater than that which was assigned to that patient per the study protocol. If an overdose occurs, Karyopharm should be notified immediately, and the patient should be observed closely for AEs. Resulting symptoms should be treated, as appropriate, and the incident of overdose and related AEs and/or treatment should be recorded. Overdose is to be reported on an SAE report form to Karyopharm pharmacovigilance regardless of whether or not an AE or SAE has occurred due to the overdose. If the overdose is associated with an SAE, the SAE report form must be submitted to Karyopharm pharmacovigilance within 24 hours of awareness.  If there is no AE or SAE, the overdose report must be submitted within 24 hours of awareness.  
7.13.2 Abuse, Misuse, or Medication Error 
 Abuse is the persistent or sporadic, intentional excessive use of the study drug which is accompanied by harmful physical or psychological effects.   A medication error is any preventable incident that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professionals or patients. Such incident may be due to health care professional practice, product labeling, packaging and preparation, procedures for administration, and systems, including prescribing; order communication; and nomenclature; compounding; dispensing; distribution; administration; e ducation; monitoring; and use.’ 
 All occurrences of abuse, misuse or medication error with Karyopharm drug are to be reported on an SAE report form to Karyopharm pharmacovigilance regardless of whether or not an AE or SAE has occurred due to the abuse, misuse or medication error.  If the abuse, misuse or medication error is associated with an SAE, the SAE report form must be submitted to Karyopharm pharmacovigilance within 24 hours of awareness.  If there is no AE or SAE, the report must be submitted as soon as possible.  
7.13.3 Occupational Exposure 
 Occupational exposure is the exposure to a study drug as a result of one’s professional or non-professional occupation.    All occurrences of occupational exposure with Karyopharm drug are to be reported on an SAE report form to Karyopharm pharmacovigilance regardless of whether or not an AE or SAE has 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
52 occurred due to the occupational exposure.  If the occupational exposure is associated with an SAE, the SAE report form must be submitted to Karyopharm pharmacovigilance within 24 hours of awareness.  If there is no AE or SAE, the report must be submitted as soon as possible.  7.14 Data Safety Monitoring Plan 
 The data and safety monitoring plan will involve the continuous evaluation of safety, data quality and data timeliness . Investigators will conduct continuous review of data and patient safety at 
their regular Disease Group meetings (at least monthly) and the discussion will be documented in minutes. For each dose level, the Principal Investigator, study coordinator, and s tatistician, in 
consultation with treating physicians as appropriate will review all toxicities at a given dose level to inform the model for dose level adjustments.  The Principal Investigator of the trial will 
review toxicities and responses of the trial where applicable at these disease center meetings and determine if the risk/benefit ratio of the trial changes. Frequency and severity of adverse events will be reviewed by the Principal Investigator  and compared to what is known about the 
agent/device fr om other sources; including published literature, scientific meetings and 
discussions with sponsors, to determine if the trial should be terminated before completion. Serious adverse events will be reviewed  by the OSUCCC Data and Safety Monitoring 
Committe e (DSMC). The Principal Investigator will also submit a biannual progress report that 
will be reviewed by the committee per the DSMC plan. All r eportable SAE s will be reported to 
the IRB of record as per the policies of the IRB.  Mandatory safety and trial review teleconferences will be scheduled and moderated by the Multi -
Center Trial Program (MCTP). All sites involved in the study are expected to have a representative present every month to review and discuss patients on study and other applicable agenda items. Meeting minutes will be used to document each monthly teleconference. The 
minutes will be stored in the MCTP  protocol files. 
 8. PHARMACEUTICAL  INFORMATION 
 A list of the adverse events and potential risks associated with selinexor and ibrutinib c an be 
found in Sections 7.1 and 7.2, respectively.  8.1 Selinexor Description/Availability  
Selinexor is manufactured by KABS Laboratories (Montreal, ON) for Karyopharm, Therapeutics 
(Newton, MA) using methods in accordance with Food and Drug Administration (FDA) guidelines for the manufacture and testing of antineoplastic agents for human use.  The tablets are prepared from a common blend of excipients and all tablet excipients are GRAS (generally regarded as safe) 
listed and suitable for use in pharmaceuticals.  Selinexor is an investigational agent supplied to investigators of this study by Karyopharm Therapeutics at no cost. 
 
Sites must request study drug by submitting an order form directly to the drug depot in order for the study drug to be  shipped to the site pharmacy. The drug order forms will also be used for re -
supply of study medication.  Instructions for re -orders are included on the form.  Requests should 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
53 be made to allow for 5 -7 days for delivery. The investigator (or designee) will verify and 
acknowledge receipt of all study drug shipment by signing and returning all required forms.  
 
8.1.1 Selinexor Composition and Preparation 
 
Selinexor will be supplied in 20 mg tablets in wallet- sized blister packs (12 tablets per blister 
pack).  Each wallet -size blister package of selinexor tablets will be labeled in accordance with 
current International  Conference on Harmonization (ICH), Good Clinical Practice (GCP), and 
specific regulatory requirements, e.g., FDA, Health Canada, EMA, etc.  Blister packages for take-home use may require additional in-pharmacy labeling with take-home and patient- specific 
instructions (such as exact dose) depending on country- specific regulations or laws.  
 
8.1.2 Selinexor Administration  
 Each dose will consist of selinexor tablet(s) for oral administration on a fixed dose basis.  Selinexor oral doses are given Days 1, 8, and 15 o f each 28 day cycle.  
 
Selinexor tablets are to be taken with at least 120 mL (4 ounces) of fluids (water, juice, etc.) at 
approximately the same time each day.  Selinexor tablets should not be crushed because of 
increased risk of dermatologic toxicity if the powder comes in contact with skin. 
Selinexor for the study are provided by Karyopharm Therapeutics and will be labe led as per the 
applicable regulations. Stu dy drug must be requested by submitting an order form directly to the 
drug depot in order for the study drug to be shipped to the site pharmacy. The Investigator (or 
designee) will verify and acknowledge receipt of all study drug shipments by signing and returning all required forms.   Selinexor accountability records will be maintained at each participating institution  and must be 
available for review when requested for auditing purposes and at time of study close out.   All medication must be stored in a secure area under the proper storage requirements with access restricted to the site staff pharmacist or designee(s).   Selinexor should not be used for any purpose outside the scope of this protocol, nor can selinexor be transferred or licensed to any party not participating in the clinical study. D ata for selinexor 
are confidential and proprietary and shall be maintained as such by the Investigators.  
8.1.3 Drug Storage 
 Selinexor tablets will be stored at or below 30 ˚C (86 ˚ F) in white high-density polyethylene 
(HDPE) bottles  or in blister packs , in a locked and secured area with restricted access.  Selinexor 
tablets can be stored at room temperature (recommended) or refrigerated, but should not be stored frozen or at freezer temperatures. Selinexor tablets are currently in on -going stability 
studies. The current expiry is 24 months from date of manufacture, and will be extended when further stability data becomes available.   All medication must be stored in a secure area under the 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
54 proper storage requirements with access restricted to the site staff pharmacist or  designee(s).  
 
8.1.4 Accountability and Destruction of Investigational Medicinal Product  
 The Principal Investigator (or an authorized designee) at each participating instit ution must 
maintain a careful record of the inventory of the Investigational medicinal product received using the Drug Accountability Form. The study drug will be destroyed as per site’s destruction policies and documentation of study drug destruction will be kept.  Both used and unused study drug may be returned to the sponsor if requested by the sponsor.  
8.1.5 Safety Considerations 
 Anorexia/Weight Loss  Selinexor treatment can cause reduced food (caloric) intake and concomitant weight loss. Patients should be advised to monitor their weight carefully, and to try different foods in order to maintain a healthy caloric intake.  See Section 4.4  and 4.5 for detailed supportive care 
recommendations for anorexia.  
 Fatigue  Fatigue may be related to underlying malignancy, selinexor side effects, side effects of other agents , or concurrent morbidities. Fatigue may also be related to anorexia and/or dehydration, so 
caloric and fluid intake should be optimized in all patients .  See Section 4. 5 for detailed 
supportive care recommendations for anorexia and fatigue.  Nausea/Vomiting  Supportive care for nausea and vomiting should be given promptly. Prophylactic treatment can be considered in case of previous side effect of nausea and vomiting with prior anti- cancer 
therapy. The treatment should start with the first sign of nausea. Standard anti- emetics are 
allowed and strongly recommended.  See Section 4.4 and 4.5 for detailed supportive care 
recommendations for emesis.  
 Thrombocytopenia  The etiology of thrombocytopenia in patients treated with selinexor is unclear, but has been experienced by patients on the phase I study.  See Section 5. 1 for dose adjustments related to 
thrombocytopenia.  Infection  
 Selinexor may lead to neutropenia.  Patients should report any symptoms or signs of infection such as fever, pain, sweating, redness t o their physician immediately. Section  5.4 for dose 
adjustments related to infection . 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
55  Liver Function Abnormalities  
 In some species such as dogs (but not rodents or monkeys), selinexor can cause increases in liver function tests and these should be follow ed carefully. Patients should minimize their use of  
acetaminophen on dosing days as these drugs can cause liver toxicity.   8.2 Ibrutinib Description/Availability  
 Ibrutinib is an oral inhibitor of Bruton’s tyrosine kinase.  The compound is manufactured by Pharmacyclics, Inc (Sunnyvale, CA) using methods in accordance with Food and Drug 
Administration (FDA) guidelines for the manufacture and testing of antineoplastic agents for human use.    
8.2.1 Ibrutinib Composition and Preparation 
 Ibrutinib for oral administration is supplied as either capsules or tablets.  The capsules are hard gelatin capsules containing micronized ibrutinib and the following excipients: microcrystalline cellulose; croscarmellose sodium; sodium lauryl sulfate; may contain magnesium stearate. Capsules are manufactured as 140mg in a size 0, gray, hard gelatin capsule. Capsules are packaged in high-density polyethylene (HDPE) bottles with an induction seal and a child resistant screw top cap. Each bottle contains 92 capsules. Ibrutinib capsules are to be dispensed in their original containers.  The tablet formulation is manufactured as 140, 280, or 420 mg and is dispensed as a blister pack.  
  
8.2.2 Ibrutinib Administration  
 Ibrutinib should be taken with 8 ounces (approximately 240 mL) of water (avoid grapefruit or Seville orange juice due to CYP450 3A4 inhibition). Each dose of ibrutinib should be taken at least 30 minutes before eating or at least 2 hours after a meal, at approximately the same time each day. The capsules or tablets should be swallowed intact and subjects should not attempt to open capsules or dissolve them in water.  If a dose is missed, it can be taken up to 6 hours after the scheduled time with a return to the normal schedule the following day. If it has been greater than 6 hours, the dose should not be taken and the subject should take the next dose at the scheduled time the next day. The missed dose will not be made up and must be reported at the next scheduled visit.  Ibrutinib should be held for any procedure using the following guidelines:   
• For any surgery or invasive procedure requiring sutures or staples for closure, ibrutinib should be held at least 7 days prior to the intervention and should be held at least 7 days after the procedure and restarted at the d iscretion of the investigator when the surgical 
site is reasonably healed without serosanguineous drainage or the need for drainage 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
56 tubes.  
• For minor procedures (i.e. such as a central line placement, needle biopsy, thoracentesis, or paracentesis) ibrutinib should be held for at least 3 days prior to the procedure and should not be restarted for at least 3 days after the procedure. For bone marrow biopsies that are performed while the subject is on ibrutinib, it is not necessary to hold ibrutinib for these procedures.  
• For emergency procedures, ibrutinib should be held after the procedure until the surgical site is reasonably healed, for at least 7 days after the urgent surgical procedure. 
 Ibrutinib will be provided as standard of care through individual patient insurance authorization.  Ibrutinib  accountability records will be maintained at each participating institution  and must be 
available for review when requested for auditing purposes and at time of study close out.   All medication must be stored in a  secure area under the proper storage requirements with access 
restricted to the site staff pharmacist or designee(s).   
8.2.3 Ibrutinib Safety Considerations 
 Nausea/Vomiting  Supportive care for nausea and vomiting should be given promptly. The treatment should start with the first sign of nausea. Standard anti- emetics are al lowed and strongly recommended.  See 
Section 4.4 for detailed supportive care recommendations for emesis.  Diarrhea  
 Supportive care for diarrhea should be given promptly.  S ee Section 4.4 for detailed supportive 
care recommendations for diarrhea . 
 Bleeding  
 Life-threatening bleeding adverse events were recorded in patients who were concurrently taking 
ibrutinib and warfarin.  If a patient requires warfarin therapy, they are i neligible for this trial.  
 Atrial fibrillation  
 Ibrutinib has been noted to lower the heart rate and patients taking this drug have a slightly increased risk of atrial fibrillation.  ECG is required prior to initiation of ibrutinib.  
 9. CORRELATIVE  STUDIES  
 
9.1 Ibrutinib Steady State Plasma Levels  (Cohorts 1 and 2 only) 
9.1.1 Objective: To measure steady -state levels of ibrutinib for comparison with historical 
data to assess for significant drug-drug interactions with selinexor.   
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
57 9.1.2 Collection of Specimen(s): Tw o plasma samples will be collected predose on Cycle 1, 
days 15 and 16. Each sample must be drawn prior to the ibrutinib dose that day. 
9.1.3 Handling of Specimens(s) Approximately 5 mL of blood will be collected in sodium heparin (green top) tubes, placed on ice and immediately centrifuged at 1,200 x g for 10 minutes to isolate plasma. Plasma will be frozen in two separate vials and stored in a -70°C (or less) freezer. Each sample will be labeled with the protocol number, patient number, reference time point relative to the protocol, date and time the sample was obtained, and date and time the sample was placed in the - 70°C freezer.  
9.1.4 Shipping of Specimen(s): Samples will be retained until a batch of samples is available for each subject. Samples will then be shipp ed in batches on dry ice via FedEx Monday through 
Thursday to: The OSU Pharmacoanalytical Shared Resource (PhASR)  
Attn: Jiang Wang, PhD 441 Biomedical Research Tower  
460 West 12th Avenue Columbus, Ohio 43210 Phone: (614) 688-0578 Fax: (614) 292-7766 Email: PhASR@osumc.edu 
8.2.5  Sites Performing Correlative Study: OSU PhASR  
 9.2 Pharmacodynamic (PD) properties of Selinexor  
9.2.1 Objective s:   
To evaluate the inhibition of the B-cell receptor signaling pathway in patients with relapsed or refractory CL L who receive the combination of selinexor and ibrutinib. 
To evaluate the change in localization of tumor suppressor proteins (such as P53, p73, Bcl-2, c- myc, Bcl -6, NFκB/IκB, FOXO3a and FOXO1) in patients with relapsed or 
refractory CLL following treatmen t with selinexor and ibrutinib. 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
58 9.2.2 Collection of Specimen(s): Markers of B -cell receptor signaling pathway activation 
(such as phosphorylation of BTK, Plc ᵧ, AKT, and ERK) will be assessed via 
immunoblot.  Localization of tumor suppressor proteins will be assessed with confocal microscopy.  Expression of targets regulated by these proteins (NF κB, Mcl1, 
Tcl1, BTK, p21, BCLxL, cMyc) will be assessed by real time PCR and immunoblot. Four 8.5-mL ACD yellow top tubes and two 6- mL purple (EDTA) topped Vacutainer 
tubes of whole blood will be collected pretreatment and 4 hours post- treatment on 
Cycle 1 Day 1, pretreatment on Cycle 1 Day 2, Cycle 1 Day 8, and Cycle 2 Day1. For cohort 3, samples will be collected C1D1, C2D1, C6D1, and C14D1 
9.2.3 Handling of Specimens(s): Specimens should be stored at room temperature until sent to the laboratory for processing.   
9.2.4 Shipping of Specimen(s): Ship to: OSU CLL Experimental Therapeutics Laboratory  
410 W 12th Avenue 4th Floor CCC Building Columbus, OH 43210 Phone (614) 292-8824 
9.2.5 Site(s) Performing Correlative Study:  Ohio State University  
 9.3 Pharmacogenomics (PGx) (Cohorts 1 and 2 only) 
9.3.1 Collection of Specimen(s): A single whole blood sample will be collected in a 6 mL lavender top (K2EDTA) collection tube prior to treatment on day 1 of cycle 1. 
9.3.2 Handling of Specimens(s): The tube should be inverted 8-10 times then whole blood immediately separated into two equal volumes into cryo -storage tubes and 
immediately stored in a freezer maintained at  or less than - 70°C. DNA will later be 
extracted, and PGx analysis will be conducted using multiplexed or gene- specific 
methods to assess polymorphisms in drug metabolizing enzymes, transporters, target genes and/or genes relevant in the targeted BTK or XP O1 pathways. 
9.3.3 Shipping of Specimen(s):  The OSU Pharmacoanalytical Shared Resource  
Attn: Ming Poi, PhD  
441 Biomedical Research Tower  
460 West 12th Avenue Columbus, Ohio 43210 Phone: (614) 688-0578 Fax: (614) 292-7766 Email: PhASR@osumc.edu 
9.3.4 Site Performing Correlative Study: OSUCCC, Pharmacoanalytical Shared Resource  
 9.4 Primary a nd Secondary Resistance Studies  
9.4.1 To preliminarily assess potential causes for primary and secondary resistance to selinexor and ibrutinib. 
9.4.2 Collection of Specimen(s):  Buccal swab will be obtained at baseline for germline DNA and SNP filtering.  Subjects relapsing during ibrutinib  will be examined for 
baseline characteristics and will potentially be subjected to extensive molecular 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
59 characterization to determine the reason for drug resistance. This could include genomic, transcriptome, proteomic, biochemical, plasma (including exosomes) or epigenetic studies of baseline and serial samples.  Additionally, as common mutations of ibrutinib resistance have been characterized by our group, we will monitor serially (Q 3m) from blood/plasma mRNA of C381S BTK and PLCγ 2 and XPO1 by ion 
torrent analysis. Four  8.5 mL yellow ACD tubes and one 6- mL lavender EDTA tubes 
will be obtained every 3 months and transported to the OSU CLL Experimental therapeutics  labor atory. Additionally, five 8.5-mL yellow ACD tubes and one 6- mL 
lavender EDTA tube at time of relapse should be drawn and transported to the O SU 
CLL Experimental T herapeutics laboratory.  Lymph node material in ex cess to that 
required for clinical diagnosis (pre- treatment or at relapse) may also be used for these 
studies.  This will be obtained from pathology and fresh tissue preferred. Excess 
material from samples may be used for additional studies related to mechanism action and toxicity of these two drugs or biology of CLL. These samples may be shared with other investigators working collaboratively with OSU.  
9.4.3 Handling of Specimens(s): Material should be transported or shipped to the OSU CLL Experimental Therapeutics Laboratory. 
9.4.4 Shipping of Specimen(s): Ship to: OSU CLL Experimental Therapeutics Laboratory  
410 W 12th Avenue 4th Floor CCC Building Columbus, OH 43210 Phone (614) 292-8824 
9.4.5 Site Performing Correlative Study: OSU CLL Experimental Therapeutics Laboratory  
  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
60 10. STUDY CALENDAR  
Pre-study evaluations must be completed within 2 weeks of study registration, unless otherwise 
noted. Karyotype, FISH, bone marrow biopsy, peripheral blood immunophenotyping, and CT scans must be performed within 45 days of study registration. Informed consent must be obtained within the time frame specified by local policy.  IgVH mutational status does not need to be repeated if performed previously. It is acceptable for individual cycles to be gin ≤ a 24-hour 
(business day) window before and after the protocol-defined date for Day 1 of a new cycle. For example, if the treatment due date is a Friday, the window for treatment includes the preceding Thursday through the following Monday. In addition, patients are permitted to have a new cycle of therapy delayed up to 7 days for major life events (e.g., serious illness in a family member, major holiday, vacation that cannot be rescheduled) without this being considered a protocol violation. New cycles of ibrutinib can be started up to 7 days before the protocol- defined date for 
major life events. Documentation to justify a delay or advance of a cycle should be provided.  Additionally, all tests and observations associated with the beginning of a cycle may be performed up to 48 hours prior to beginning the cycle of therapy.  Calendar for dose escalation and expansion cohorts 
General Study Calendar  
Cycle  Pre- 
Study 1 2-3 4-
6 7+k Off 
Treatment  Follow -
upl 
Day 1 8 15 22 1 15 1 1 
Eligibility checklist  X           
Informed consent  X           
Historya X           
Progress noteb  X X X X X X X X X Xl 
Physical exam  X X X X X X X X X X Xl 
Ophthalmologic 
examc X         X  
Concurrent meds  X X X X X X X X X   
Vital signs/weight/  
height/BSA  X X X X X X X X X X  
ECOGd X X X X X X X X X X  
CBC, dif, platelets  X X X X X X X X X X  
Coagulatione X X X X X X X X X X  
Chemistryf, Ca, Mg, 
Phos  X X X X X X X X X X  
Liver function testsg X X X X X X X X X X  
LDH  X X    X      
Uric acid  X X          
Peripheral blood 
immunophenotyping  X     Xm  Xn Xo X Xl 
Quant 
immunoglobulins  X           
SPEP with X           
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
61 immunofixation  
CLL karyotype, 
FISH panelh & 
IgVH mutational 
analysis  Xi           
Pregnancy testj X           
HIV/Hep  X           
Buccal swab  X           
ECG  X           
Dispense KPT -330  X    X  X X   
Adverse event 
evaluation  X X X X X X X X X X Xh 
PET/CT or CT 
scans  X     Xm  Xn Xo X Xh 
Bone marrow 
biopsy and aspirate  Xp       Xq Xq  Xq 
Histologic review  Xr           
Correlative studies  See Correlative Study Calendar  
  
a. Initial medical history should include: baseline symptoms ; a detailed history of prior 
cancer therapies including start and stop dates, disease progression during or after therapy, as well as discontinuations due to intolerability or any other serious illness; family and social history; calculation of Rai Stage ( for CLL patients), MIPI (for MCL 
patients), or IPI (NHL patients other than MCL; see Appendix C). 
b. Progress notes should include: new symptoms or adverse events, ECOG performance status (Appendix A), documentation of physical exam, status of disease. 
c. Ophtha lmologic exam: required at screening, if clinically indicated during study, and at 
final visit. Prior to dilation: best corrected visual acuity, visual field examination via automated perimetry, tonometry, and color vision test.  Dilated fundoscopy and sli t lamp 
exam including anterior segment photos to document lens clarity. 
d. For ECOG performance status, see Appendix A 
e. Prothrombin time, international normalization ratio, and activated partial thromboplastin 
time 
f. Sodium, potassium, bicarbonate, BUN, calcium, chloride, creatinine 
g. Albumin, alkaline phosphatase, total bilirubin, total protein, SGOT [AST], SGPT [ALT]  
h. FISH panel will use probes to detect for abnormalities in chomosomes 13q, 12, 11q, and 17p. 
i. For CLL patients only. 
j. Pregnancy tests for females of childbearing potential. A female of childbearing potential (FCBP) is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). Female of childbearing potential must have a negative serum β -Hcg pregnancy 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
62 test result within 3 days of first study dose. 
k. For cycles 7 and higher, patient will be required to return for evaluation and to receive KPT -330 every 3
rd month ( eg. Cycle 7 Day 1, Cycle 10 Day 1, Cycle 13 Day 1….) 
l. Reassessment off therapy will occur 4 weeks from the last dose of study therapy.  For patients removed from study for reasons other than disease progression, reassessment will then occur then every 6 months until progression or an alternative therapy is started. 
m. Cycle 2 Day 1 only. 
n. Cycle 4 Day 1 only. 
o. Restaging scans and immunophenotyping will be performed every 3 cycles for the first year and then every 6 months thereafter. 
p. Bilateral bone marrow biopsies are preferred for lymphoma patients. 
q. A bone marrow biopsy and aspirate should be performed to confirm a complete response if there was bone marrow involvement at diagnosis, clinical MRD flow should be performed in this case. 
r. For patients with DLBCL only: Paraffin block must be submitted for immunohistochemistry evaluation of CD10, bcl-6, and MUM-1 to determine ABC vs GCB s ubtype. Biopsy to confirm histologic review does not need to be repeated for pre-
study requirements, so long as previously obtained tissue confirms patient meets histologic eligibility criteria prior to study registration.  
   
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
63 Cohort 3 Study 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
1 Calendar  
Cycle  Pre- 
Study Day 1, 
Cycles 1 -3 Day 1, Cycles 
6, 9, 12 Cycle 14 Day 1  Day 1, every 3 
cycles following 
cycle 14 
(continue 
ibrutinib) C17, 
20, 23, 26, etc.  Day 1, every 
3 cycles 
following 
cycle 14 (off 
therapy)  Follow -up 
(off 
therapy)j 
Eligibility checklist  X       
Informed consent  X       
Historya X       
Progress noteb  X X X X X X 
Physical exam  X X X X X X X 
Ophthalmologic 
examc X       
Concurrent meds  X X X  X   
Vital signs/weight/  
height/BSA  X X X  X X  
ECOGd X X X  X X  
CBC, dif, platelets  X X X  X X  
Coagulatione X X X  X   
Chemistryf, Ca, Mg, 
Phos  X X X  X X  
Liver function testsg X X X  X   
LDH  X       
Uric acid  X       
Peripheral blood 
immunophenotyping  X  X   X X 
Quant 
immunoglobulins  X  X     
SPEP with 
immunofixation         
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
2 CLL karyotype, 
FISH panelh & 
IgVH mutational 
analysish X       
Pregnancy testi X       
HIV/Hep  X       
Buccal swab  X       
ECG  X       
Adverse event 
evaluation  X X   X   
PET/CT or CT 
scans  X     Xk X 
Bone marrow 
biopsy and aspirate  X   X    
Correlative studies  X X X X X X  
a. Initial medical history should include: baseline symptoms ; a detailed history of prior cancer therapies including start and stop 
dates, disease progression during or after therapy, as well as discontinuations due to intolerability or any other serious illness; family and social history; calculation of Rai Stage (for CLL patients)  
b. Progress notes should include: new symptoms or adverse events, ECOG performance status (Appendix A), documentation of physical exam, status of disease.  
c. Ophthalmologic exam: require d at screening  and if clinically indicated during study. Prior to dilation: best corrected visual 
acuity, visual field examination via automated perimetry, tonometry, and color vision test.  Dilated fundoscopy and slit lamp exam including anterior segment photos to document lens clarity. 
d. For ECOG performance status, see Appendix A 
e. Prothrombin time, international normalization ratio, and activated partial thromboplastin time  
f. Sodium, potassium, bicarbonate, BUN, calcium, chloride, creatinine 
g. Albumin, alkaline phosphatase, total bilirubin, total protein, SGOT [AST], SGPT [ALT]  
h. Only if not done prior to initiation of ibrutinib 
i. Pregnancy tests for females of childbearing potential. A female of childbearing potential (FCBP) is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal (amenorrhea following cancer  therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had 
menses at any time in the p receding 24 consecutive months). Female of childbearing potential must have a negative serum β -
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
3 Hcg pregnancy test result within 3 days of first study dose. 
j. Reassessment off therapy will occur 4 -6 weeks from the last dose of study therapy.  For patients rem oved from study for 
reasons other than disease progression, reassessment will then occur then every 6 months until progression or an alternative therapy is started.  
k. Restaging scans and immunophenotyping will be performed every 3 cycles for the first year and then every 6 months thereafter.  
Bilateral bone marrow biopsies are preferred for lymphoma patients. l. A bone marrow biopsy and aspirate should be performed to confirm a complete response if there was bone marrow involvement at diagnosis , clinical MRD flow should be performed in this case. 
4  
  
 
Cycle  1 2 Q3 
Cy
cles Rela
pse 
Day 1 2 8 15 16 1 1 
Time* Pr
e-
do
se1 30
-
mi
n 
po
st 
do
se2 1-
hr 
po
st 
do
se1 2-
hr 
po
st 
do
se1 4-
hr 
po
st 
do
se3 8-
hr 
po
st 
do
se4 24
-hr 
po
st 
do
se5 Pr
e-
do
se1 Pr
e-
do
se1 30
-
mi
n 
po
st 
do
se2 1-
hr 
po
st 
do
se1 2-
hr 
po
st 
do
se1 4-
hr 
po
st 
do
se3 8-
hr 
po
st 
do
se4 24
-hr 
po
st 
do
se5 Pr
e-
do
se1  Any 
                   
                   
Ibruti
nib 
PK 
(Section 
9.2)         A      A    
PD B -
cell Receptor Signaling 
Pathw
ay and 
tumor suppressor localiz
ation  
(Secti
on 
9.3)$ B    C  C C        C   
Pharm
aco-
genomics (PGx)  
(Section 
9.5) D                  
Resist
ance Studies 
(Section 
9.6)                 E F 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
5  
A. For Ibrutinib PK plasma: Approximately 5 mL of blood will be collected in sodium heparin (green top) tubes, placed on ice and immediately centrifuged at 1,200 x g for 10 minutes to isolate plasma. Plasma will be frozen in two separate vials and stored in a -70°C (or less) freezer. Each sample will be labeled with th e protocol number, patient 
number, reference time point relative to the protocol, date and time the sample was obtained. 
B. Correlative study samples (4 x 8.5-mL ACD yellow top tube, and 6- mL potassium EDTA 
[lavender-top vacutainer] from blood) should be draw n at baseline.  
C. Correlative study samples (2 x 8.5-mL ACD yellow top tube and 6- mL potassium EDTA ) 
should be drawn on Cycle 1 Day 1; 4 hours post- treatment and Cycle 1 Day 8 and Cycle 
2 Day 1 pretreatment.  Cohorts 1 and 2 only 
D. A PGx blood sample (1 x 6- mL EDTA lavender top) should be collected prior to dosing 
on Cycle 1 Day 1. Cohorts 1 and 2 only 
E. To monitor for resistance:   Four x 8.5 mL ACD yellow top tubes and 1 x 6- mL EDTA 
lavender tubes will be obtained every 3 cycles and transported or shipped to the OSU 
Experimental Therapeutics Laboratory .  This will start at cycle 4.  Lymph node material 
in excess to that required for clinical diagnosis (pre- treatment or at relapse) may also be 
used for these studies. Cohorts 1 and 2 only   
F. To evaluate resistant samples:   Five  x 8.5- mL ACD  yellow top tubes and 1 x 6- mL 
EDTA lavender top tube at time of relapse should be drawn and transported shipped to the OSU Experimental Therapeutics Laboratory .  Lymph node material in excess to that 
required for clinical diagn osis (pre -treatment or at relapse) may also be used for these 
studies. Cohorts 1 and 2 only     
0 11. MEASUREMENT OF EFFECT 
 
11.1 Response Criteria  
 Response will be assesse d by the International Working Group (IWG) Response Criteria for 
NHL p atien ts
42 and the International Workshop on CLL (IWCLL) criteria14 for CLL patients 
after 1  and 3 months of therapy, then  every 3 month s for 1 y ear, and then every 6 months 
thereafter until disease progression with no maximum treatment length.    
11.1.1 Definitions  
 Evaluable for toxicity.  All patients will be evaluable for toxicity from the time of their 
first treatment with selinexor.  Evaluable for response.  Only those patients who have received at least four weeks of 
therapy and have had their disease re- evaluated will be considered evaluable for 
response.  These patients will have their response classified according to the definitions stated below.  (Note:  Patients who exhibit objective disease progression prior to the end of 4 weeks will also be considered evaluable.) 
 
11.1.2 Response Criteria for N
 HL 
 Definiti on of Response for NHL  Patients:  Criteria for response will utilize the IWG  Response 
Criteria for NHL patients
42. 
 
Complete Response (CR):   
Complete disappearance of all detectable clinical evidence of disease and disease related  
symptoms if present before therapy.  
• In patients with no pre -treatment PET scan, or if the PET scan was positive before 
therapy, a post -treatment residual mass of any size is permitted as long as it is PET - 
negative.  
• The spleen and/or liver, if considered enlarged prior to therapy on the basis of a physical examinati on or CT scan, should not be palpable on physical examination and should 
be considered normal size by imaging studies, and nodules related to lymphoma should disappear.  However, determination of splenic involvement is not always reliable because a spleen considered normal in size may still contain lymphoma, whereas an enlarged  spleen may reflect variations in anatomy, blood volume, the use of 
hematopoietic growth factors, or causes other than lymphoma. 
• If the bone marrow was involved by lymphoma before treatment, the infiltrate must 
have cleared on repeat bone marrow biopsy.  The biopsy sample on which this determination is made must be adequate (with a goal of > 20 mm unilateral core). If the sample is indeterminate by morphology, it should be negative by immunohistochemistry. A sample that is negative by immunohistochemistry, but that demonstrates a small population of clonal lymphocytes by flow cytometry, will be considered a CR until data become available demonstrating a clear difference in pat ient 
outcome. 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
1  Partial Response (PR):  
• At least a 50% decrease in the sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses. These nodes or masses should be selected prior to initiation of therapy according to all of the following: a) they should be clearly measurable in at least two perpendicular dimensions; b) if possible, they should be from disparate regions of the body; and c) they should include mediastinal and retroperitoneal areas of disease whenever these sites are involved.  
• No increase should be observed in the size of other nodes, liver, or spleen.  
• Splenic and hepatic nodules must regress by ≤  50% in their SPD, or, for single nodules, 
in the greatest transverse diameter.  
• With the exception of splenic and hepatic nodules, involvement of other organs is 
usually assessable and no measurable disease should be present.  
• Bone marrow assessment is irrelevant for determination of a PR if the sample was 
positive before treatment. However, if positive, the cell type should be specified (e.g., large- cell lymphoma or small neoplastic B cells). Patients who achieve a CR by the 
above criteria, but who have persistent morphologic bone marrow involvement, will be considered partial responders. When the bone marrow  was involved before therapy and 
a clinical CR was achieved, but with no bone marrow assessment after treatment, patients should be considered partial responders.  
• No new sites of disease should be observed.  
• If performed, the post -treatment PET should be positive in at least one previously 
involved site. 
 Stable Disease (SD):  
Patient fails to attain the criteria needed for a CR or PR, but does not fulfill those for progressive disease (see below). If performed, the PET should be positive at prior sites of disease, with no new areas of involvement on the post- treatment CT or PET.  
 Progression (PD) or Relapse:  
• Lymph nodes should be considered abnormal if the long axis is > 1.5 cm, regardless of the short axis. If a lymph node has a long axis of 1.1 to 1.5 cm, it should only be considered abnormal if its short axis is > 1.0. Lymph nodes ≤ 1.0 by ≤ 1.0 will not be considered as abnormal for relapse or progressive disease.  
• Appearance of any new lesion > 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size. Increased FDG uptake in a previously unaffected site should only be considered relapsed or progressive disease after confirmation with other modalities. In patients with no prior history of pulmonary lymphoma, new lung nodules identified by CT are mostly benign. Thus, a therapeutic decision should not be made solely on the basis of the PET without histologic confirmation.  
• At least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be considered progressive disease, a lymph node with a diameter of the short axis of < 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
2 1.0 cm must increase by ≥ 50% and to a size of 1.5 x 1.5 cm, or > 1.5 cm in the long axis. 
• At least a 50% increase in the longest diameter of any single previously identified node 
> 1.0 cm in its short axis. Lesions should be PET- positive if a typical FDG -avid lymphoma or the lesion was 
PET- positive prior to therapy unless the lesion is too smal l to be detected with 
current PET systems (< 1.5 cm in its long axis by CT). 
 
11.1.3 Response Criteria for CLL Patients  
 Definiti on of Response for CLL Patients:  Criteria for response will utilize the IWCLL 
Response criteria
14. 
 
Complete response (CR):  
CR requires all of the following criteria as assessed at least 2 months after completion of therapy:  
• Peripheral blood lymphocytes (evaluated by blood and differential count) below 4 x 10
9/L (4000/μL).  The presence of minimal residual disease (MRD) after therapy 
should be assessed.  The sensitivity of the method used to evaluate for MRD should be reported. 
• Absence of significant lymphadenopathy (e.g., lymph nodes >1.5 cm in diameter) by 
CT scan  of the abdomen, pelvis, and thorax. 
• No hepatomegaly or splenomegaly by physical examination. 
• Absence of constitutional symptoms.  
• Blood counts above the following values:  
o Neutrophils more than 1.5 x 10
9/L (1500/μL) without need for exogenous 
growth factors.  
o Platelets more than 1 00 x 109/L (100 000/μL).  
o Hemoglobin more than 110 g/L (11.0 g/dL) without red blood cell transfusion or need  for exogenous erythropoietin.  
• A marrow aspirate and biopsy should be performed at least 2 months after the last treatment  and if clinical and la boratory results as above demonstrate that a CR has 
been achieved.  
o To define a CR, the marrow sample must normocellular for age, with less than 
30% of nucleated cells being lymphocytes. Lymphoid nodules should be absent. If lymphoid nodules are present then these nodules should be recorded as nodular PR. However, immunohistochemistry should be performed to define whether these nodules are composed primarily of T cells or lymphocytes other than CLL cells or of CLL cells. If the marrow is hypocellular, a repeat determination should be performed after 4 weeks, or until peripheral blood counts have recovered. However, this time interval should not exceed 6 months after the last treatment. A marrow biopsy should 
be compared with that of pretreatment marrow.   The quality of the CR should 
be assessed for MRD by flow cytometry or by immunohistochemistry (IHC).  
 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
3 CR with incomplete marrow recovery (CRi):  
All the criteria for a CR (including the marrow examination) have been met though there is persistent anemia or th rombocytopenia or neutropenia apparently unrelated to CLL but related to 
drug toxicity.   
 Partial response (PR)   PR is defined as follows:  
• A decrease in the number of blood lymphocytes by 50% or more from the value 
before  therapy.  
• Reduction in lymph node size by 50% or more either in the sum products of up to 
6 lymph nodes, or in the largest diameter of the enlarged lymph node(s) detected prior to therapy.  
• No increase in any lymph node, and no new enlarged lymph node. In small lymph nodes (< 2 cm), an increase of less than 25% is not considered to be significant.  
• A reduction in the noted pretreatment enlargement of the spleen or liver by 50% 
or more, as detected by CT scan.  
• The blood count should show one of the following results:   
• Neutrophils more than 1.5 x 10
9/L (1500/μL) without need for exogenous growth 
 factors.  
• Platelet counts greater than 100 x 109/L (100 000/μL) or 50% improvement over  
baseline.  
• Hemoglobin greater than 110 g/L (11.0 g/dL) or 50% improvement over baseline  
without requiring red blood cell transfusions or exogenous erythropoietin.  
 
Progressive Disease:  
Characterized by at least one of the following:  
• Appearance of any  new lesion, such as enlarged lymph nodes (>1.5 cm), 
splenomegaly, hepatomegaly, or other organ infiltrates.  
• An increase by 50% or more in greatest determined diameter of any previous site.  
• An increase in the previously noted enlargement of the liver or spleen by 50% or more or the de novo appearance of hepatomegaly or splenomegaly.  
• An increase in the number of blood lymphocytes by 50% or more with at least 5000 B-lymphocytes per microliter.  
• Transformation to a more aggressive histology (e.g., Richter syndrome). Whenever possible, this diagnosis should be established by lymph node biopsy.  
• Occurrence of cytopenia (neutropenia, anemia, or thrombocytopenia) attributable 
to CLL.  During therapy, cytopenias cannot be used to define disease 
progression.  
• The progression of any cytopenia (unrelated to autoimmune cytopenia), as 
documented by a  decrease of Hb levels by more than 20 g/L (2 g/dL) or to less 
than 100 g/L (10 g/dL), or by a decrease of platelet counts by more than 50% or to 
less than 100 x 10
9/L (100 000/μL), which occurs at least 3 months after 
treatment, defines disease progression, if the marrow biopsy demonstrates an infiltrate of clonal CLL cells.  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
4  Stable Disease:  
Patients who do not fulfill the criteria for complete or partial response as defined above but do not exhibit progressive disease will be considered as having stable disease.  
 
11.1.4 Duration of Response  
 Duration of overall response:  The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive di sease is objectively documented.  
 Th
e duration of overall CR is measured from the time measurement criteria are first met 
for CR until the first date that progressive disease is objectively documented.  
 Duration of stable disease :  Sta
 ble disease is measured from the start of the treatment 
until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started, including  the baseline measurements.  
 
11.1.5 Progression-Free Survival  
 PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.  
12. DATA REPORTING / REGULATORY REQUIREMENTS  
 Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 6.0 (Adverse Events: List and Reporting Requirements).  12.1 Patient Protection  
 The study will be conducted in accordance with the ethical principles of the Declaration of Helsinki and the ICH- GCP  guidelines. The Principal Investigator is responsible for ensuring that 
the study will be conducted in accordance with the protocol, the ethical principles of the Declaration of Helsinki, current ICH guidelines on Good Clinical practice (GCP) and applicable local regulatory requirements.  12.2 Patient Information  
 Before entry into the trial all eligible patients will receive written patient information describing the aim of the study, as well as probable and possible side effects and risks.  Oral information from one of the investigators or a delegated person at the institution will also be given, and the patient must have the opportunity to ask questions, and to consider participation together with his/her family members if applicable. It will be emphasized that the pa rticipation is voluntary 
and that it is the right of the patient to  refuse further participation in the study whenever he/she 
wants and that this will not influence his/her subsequent care.  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
5  12.3 Informed Consent  
 Patient / legally acceptable representative (as applicable) written consent must be obtained according to local  Institutional Review Board  requirements and must conform to the ICH 
guidelines for Good Clinical Practice, prior to any study-specific screening procedures and tr ial 
entry. The written informed consent form should be signed and personally dated by the patient or by the patient’s legally acceptable representative. A copy of the signed informed consent will be given to the patient or patient’s legally authorized representative. The original signed consent must be maintained by the Investigator at each participating site and available for inspection by 
regulatory authority at any time. A copy of all external participating site consents must also be sent to  the OSU Mult i-Institution Program Coordinator to be filed in the OSU multi- institution 
regulatory files.  12.4 Data Submission 
 The study will be managed per the Multi- Center Trial Program (MCTP) policies . Subsite data 
must be submitted to the MCTP as outlined in the protocol -specific monitoring plan, which will 
be provided to external participating sites. Data will be submitted using case report forms and the Data Submission Form cover sheet  (refer to Supplemental Forms Document) supplied by the 
MCTP . All data submitted mu st be accompanied by supporting source documents , where 
applicable and as outlined in the protocol-specific monitoring plan.  13. STATISTICAL CONSIDERATIONS  
 13.1 Study Design  
 Cohorts 1 and 2 of this study represent a prospective, multi- center, phase I dose escalation study 
in two diseases: CLL and NHL.  Dose-finding will proceed using a modified continual reassessment method  and targeting a probability of DLT<0.30. To ensure safety, the starting 
dose leve l will be the lowest dose level and dose escalation will proceed by increasing only one 
dose level at a time . Groups of 2-3 patients will be treated until convergence on an MTD, defined 
as 10-12 pat ients  treated at a particular dose level which is also a subsequently suggested dose 
level by the model or  a maximum of 36 evaluable patients, whichever occurs first. At the MTD, 
up to 10 CLL patients and 10 NHL patients will be accrued.      13.2 Sample Size/Accrual Rate  
 For cohort 1 and 2, with groups of 2-3 patients per month enrolled in the dose finding study, it is expected that approximately 9 groups of patients will be treated over 18-30 months. Expansion at the MTD is expected to accrue over 6 -12 months.  Thus, the total study duration is estimated to 
be 24-42 months. On average, we expect 32 patients to be enr olled, but the total sample size 
could be as many as 50 patients and will depend on the dose escalation and composition of CLL and NHL patients treated at the estimated MTD as part of the dose -finding portion of the study. 
 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
6 Cohort 3 will be a pilot study to gain data on the ability of selinexor to deepen responses with ibrutinib. Ten patients who have been treated with ibrutinib as their frontline therapy for CLL/SLL for at least 12 cycles and have obtained PR will be accrued  to this cohort, and 
selinexor will be added to ibrutinib for 14 more cycles. The deepening of response rate is defined as the percentage of patients who convert to a MRD negative complete response (MRD - CR) 
from PR at the end of 14 cycles of selinexor plus ibrutinib among this cohort. If we observe 3 or more patients out of 10 who achieve the conversion from PR to MRD- CR, we will consider this 
regimen promising and move it forward for further study. For various true deepening of response 
rates, the table b elow shows the probability of observing at least 3 MRD-CRs in 10 patients. For 
example, if the true deepening response rate is 30%, then the probability of declaring the regimen promising is 61.7% with 10 patients.   
True Deep ening of Response 
Rate Probability of O bserving 3 or 
More MRD -CR in 10 Patients  
0.1 0.070  
0.2 0.322  
0.25 0.474  
0.3 0.617  
0.35 0.738  
0.4 0.833  
 With an accrual rate of 2  patients per month, we expect accrual to be complete in 5 months. 
 13.3 Evaluability 
 Any patient who is eligible for the trial and has received at least one dose each of the selexinor and ibrutinib will be evaluated for toxicity (descriptive summary as well as dose escalation determination  in the first two cohorts) and for response.  Patients who are not evaluable for 
toxicity at a given dose level will be replaced.    13.4 Definition of Primary Endpoint  
 The primary endpoint is DLT.  DLT has been defined in Section 4.2 above.  13.5 Definition of Secondary Endpoints  
  
13.5.1 Toxicity will be graded by CTCAEv4.0.  A copy of the CTCAE version 4.0 can be downloaded from the CTEP web site http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm .   
 
13.5.2 Clinic al response and survival will be measured by: 
• International Working Group Criteria for NHL patients. 
• IWCLL 2008 Guidelines for CLL patients.  
Response criteria are detailed in Section 10. 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
7  Responders will be defined as those with complete response (CR) or partial response (PR).  Overall response rate (ORR) will be calculated as the number of evaluable responders divided by the total number of evaluable patients and will be analyzed by cohort. All patients who receive at least one dose of study medication  will be included in 
the ORR and progression free survival. 
 
Progression Free Survival (PFS): PFS will be calculated from the date of study enrollment to disease progression or death, whichever occurs first.  Patients who do not progress or die will be censored at the time of last contact  with response assessment by 
physical exam and laboratory studies.  
 
Overall Survival (OS): OS will be calculated from the date of study enrollment to death.  Patients who do not die will be censored at the time of last contact.  This will be analyzed 
in each cohort independently. 
 
13.5.3 Response as related to chronic lymphocytic leukemia (CLL) karyotype and IgVH mutational status.   Response criteria are detailed in Section 10. 
 
13.5.4 For Cohort 3, the rate of deepening of respons e is defined as the percentage of patients 
who attain a MRD negative complete response (MRD - CR) at the end of 14 cycles of 
selinexor plus ibrutinib. 
 13.6 Definition of Exploratory Endpoints 
 
13.6.1 Pharmacodynamic endpoints  for patients with CLL  include:   
• Markers o f downmodulation or inhibition of the B- cell receptor pathway 
including BTK expression and phosphorylation of SYK, AKT, and ERK will be assessed pretreatment and post -treatment where feasible, and reported as a 
continuous measure. 
• Change in localization of tumor suppressor and oncogene proteins and mRNAs (P53, p73, Bcl-2, c- myc, Bcl -6, NFκB/IκB, FOXO3a and FOXO1) will be will be 
assessed pretreatment and post -treatment where feasibile. Change in localization 
will be measured through blood sample collection, analyzed by immunoblot, and reported as percentage of protein fragments observed in the nucleus at each time point. 
• Potential predictive biomarkers will be assessed before and after in vitro treatment of patients’ pretreatment leukocytes via qRT- PCR and results will be reported as 
fold change from baseline.  
 
13.7 Analytic Plan for Primary Objective 
The primary objective is to identify the highest dose level of selinexor administered with ibrutinib that corresponds to an acceptable probability of DLT, defined as <0.30, in relapsed/refractory CLL and NHL patients. We do not expect that toxicity will be different 
between CLL and NHL, thereby justifying the use of both groups in dose escalation. Dosing 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
8 decisions will be made throughout the course of the trial based on a modified continual reas
sessment method  (MRCM) ,43-45 combining information assumed a priori  with observed data 
to update the estimate of the true dose-toxicity curve. A priori , it is assumed that the dose 
toxicity curve is monotonically increasing and belongs to the family of two- parameter logistic 
models, allowing the scale and slope to vary as describ ed by Piantadosi et al.45 To implement the 
model, including input of prior assumptions, data collection, and estimation of the dose- toxicity 
curve, software developed by Piantadosi (Modified Continual Reassessment Method, version 4.0) will be used. For model initiation, the a priori  curve has been defined using three 
coordinates elicited from the clinical investigators to represent a “safe”, “moderately risky” and “risky” weekly dose level of selinexor when combined with the standard dose of ibrutinib in this patient population (Figure 2). The information represented in the a priori  curve is equivalent to 
that of only 1.5 subjects, and hence, observed data accumulated throughout the trial is expected to outweigh any pseudo- data pre -specified when making dosing decisions. The target dose for 
each cohort will be identified by the software, but the starting dose and dose escalation will be constrained by design to ensure safety, as suggested in Garrett-Mayer’s 2006 tutorial, using the following rules: 1) the starting dose level will be the lowest dose level, 2) the dose level assigned for each successive cohort will be the highest dose level less than or equal to the target dose identified by the software provided there is not escalation by more than one dose level; otherwise, the target dose identified by the software will be disregarded and an increase in only one dose level at a time will be permitted, a nd 3) in the absence of DLT, decisions will be made 
following cohorts of 2 or 3 patients, cohort sizes that have been shown to balance accurate MTD information and safety.
46 We will only escalate dosing when <33% of patients at a dose level 
experience DLT, and patients will not be assigned to an escalated dose level if there is a high probability that the DLT rat e at that dose level is >30%.  It is planned that groups of 2 patients 
will be treated at lower dose levels of selinexor and groups of 3 patients will be treated beginning with dose level 3 in order to expedite the dose finding process. The trial will stop  when the 
MCRM is deemed to have adequately converged on an MTD. Specifically, the trial will stop when 10- 12 patients (depending on cohort size) are treated at a particular dose level which is also 
subsequently a suggested dose level by the model or a max imum of 36 evaluable patients have 
been treated, whichever occurs first  (approximately 6-14 cohorts) . At the time the trial 
terminates, the MTD will correspond to the highest dose level with probability of DLT<0.30. The MCRM process will be summarized, including number of DLTs observed in each cohort and the recommended dose at the end of each cohort. Using the parameter and covariance estimates from the model, and assuming parameters are from a bivariate normal distribution, repeated sampling will be used to construct an empirical distribution of the probability of DLT at the selected dose level to obtain 95% confidence intervals.   At the MTD, we will accrue up to 10 
CLL patients and 10 NHL patients in an expansion.  
 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
9 13.8 Analytic Plan for Secondary Objectives  
 
13.8.1 Toxicity  
 Toxicities will be tabulated by type and grade and displayed in summary form. In addition, the number of cycles started/completed, number of patients requiring dose reductions, and the reason for going off treatment may be summarized to assess treatment tolerability.  
 
13.8.2 Clinical Response an Survival 
 The degree of response will be summarized within each disease group and at each dose 
level. ORR will be presented for those patients treated at the MTD with an exact 95 % confidence interval.  Also among patients who are treated at the MTD, PFS and OS will be described using Kaplan -Meier curves for each disease group. In cohort 3, the 
deepening of response rate will be calculated as percentage of patients who achieve MRD -CR, and will be provided with an exact 95% confidence interval. 
 
13.8.3 Correlative endpoints 
 Formal statistical tests of hypotheses will not be performed given the nature of early clinical trials. Descriptive statistics such as mean, standard deviation, median, range, etc, for continuous variables and proportions for discrete variables will be used to summarize correlative endpoints in each of the defined strata. Graphical summaries will also be used extensively to visualize the data.  
 
Pharmacokinetic (PK) and pharmacodynamics (PD) properties of selinexor in patients with relapsed and refractory CLL and aggressive NHL will be assessed (See Section 12.4-5). PK endpoints will be computed using non- compartmental and compartmental 
methods and summarized with descriptive statistics.  
 
For expression data collected serially over time (i.e. tumor suppressor proteins and phosphoproteins), changes in expression will be explored graphically using boxplots and/or individual line plots, as well as ana lytically with repeated measures models.  
 Relationships between PK and PD endpoints with response will be largely exploratory, but may identify particular patterns of interest.  
 
 
Potential predictive Biomarker qRT -PCR fold change data will be correlated to patients’ 
clinical response once it becomes available. Predictive power of NGFR and other potential marker will be statistically tested when data of at least 100 patients will be collected from all clinical trials.    
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
10 References  
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer  J   Clin. 2012;62(1):10-
29. 
2. Ringshausen I, Schneller F, Bogner C, et al. Constitutively activated phosphatidylinositol-3 
kinase (PI -3K) is involved in the defect of apoptosis in B- CLL: association with protein kinase 
Cdelta. Blood. 2002;100(10):3741-3748. 
3. Baran -Marszak F, Boukhiar M, Harel S, et al. Constitutive and B- cell receptor -induced 
activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic 
mantle c ell lymphoma. Haematologica. 2010;95(11):1865-1872. 
4. Davis RE, Ngo VN, Lenz G, et al. Chronic active B- cell-receptor signalling in diffuse large B-
cell lymphoma. Nature. 2010;463(7277):88-92. 
5. Mohamed AJ, Yu L, Backesjo CM, et al. Bruton's tyrosine kinase (Btk): function, regulation, 
and transformation with special emphasis on the PH domain. Immunol  Rev. 2009;228(1):58-73. 
6. Satterthwaite AB and Witte ON. The role of Bruton's tyrosine kinase in B- cell development 
and function: a genetic perspective. I mmunol  Rev. 2000;175:120-127. 
7. Woyach JA, Johnson AJ, Byrd JC. The B- cell receptor signaling pathway as a therapeutic 
target in CLL. Blood. 2012;120(6):1175-1184. 8. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic 
lymphocytic leukemia. N  Engl  J  Med. 2013;369(1):32-42. 
9. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are 
associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854. 
10. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel 
prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-1847. 
11. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B -
cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100(13):4609-4614. 12. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising 
therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287-6296. 
13. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B -cell malignancies. 
J  Clin   Oncol. 2013;31(1):88-94. 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
11 14. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer I nstitute -Working Group 1996 guidelines. 
Blood. 2008;111(12):5446-5456. 
15. Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy 
is associated with distinct molecular characteristics and does not indicate a suboptimal resp onse 
to therapy. Blood. 2014. 
16. Chang BY, Furman RR, Zapatka M, et al. Use of tumor genomic profiling to reveal 
mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia.[abstract]. ASCO Meeting Abstracts. 2013;Abstract #7014. 
17. Hadzidimitriou A, Agathangelidis A, Darzentas N, et al. Is there a role for antigen selection 
in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood. 2011;118(11):3088-3095. 
18. Yu H, Pardoll D, Jove R. STATs in cancer infl ammation and immunity: a leading role for 
STAT3. Nat   Rev   Cancer. 2009;9(11):798-809. 
19. Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression profiling identifies the B- cell 
associated tyrosine kinase Syk as a possible therapeutic target in mant le cell lymphoma. 
Br  J  Haematol. 2006;132(3):303-316. 
20. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory 
mantle -cell lymphoma. N  Engl  J  Med. 2013;369(6):507-516. 
21. Younes A, Flin I, Berdeja JG, et al. Phase Ib study comgining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with CD20-positive B-cell non -Hodgkin lymphoma.[abstract]. ASCO Meeting Abstracts. 2013;Abstract #8502. 
22. Wang M, Gordon LI, Rule S, et al. A phase III study of ibrutinib in combination with bendamustine and rituximab in elderly patients with newly diagnosed mantle cell lymphoma.[abstract]. ASCO Meeting Abstracts. 2013;Abstract # TPS8613. 
23. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by 
gene-expression profiling and supervised machine learning. Nat  Med. 2002;8(1):68-74. 
24. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity 
is required for survival of activated B cell -like diffuse large B cell lymphoma cells. J   Exp   Med. 
2001;194(12):1861-1874. 
25. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B 
cell lymphoma. Science. 2008;319(5870):1676-1679. 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
12 26. Wilson WH, Gerecitano JF, Goy A, et al. The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI- 32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De 
Novo Diffuse Large B- Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open -Label, 
Phase 2 Study. ASH Annual Meeting Abstracts. 2012;120(21):686. 
27. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. 
Biochem   Pharmacol. 2012;83(8):1021-1032. 
28. Brown CJ, Dastidar SG, Quah ST, Lim A, Chia B, Verma CS. C- terminal substitution of 
MDM2 interacting peptides modulates binding affinity by distinctive mechanisms. PLoS One. 2011;6(8):e24122. 
29. Xu D, Farmer A, Chook YM. Recognition of nuclear targeting signals by Karyopherin- beta 
proteins. Curr  Opin   Struct   Biol. 2010;20(6):782-790. 
30. Arnaoutov A, Azuma Y, Ribbeck K, et al. Crm1 is a mitotic effector of Ran- GTP in somatic 
cells. Nat   Cell Biol. 2005;7(6):626-632. 
31. Obrador- Hevia A, Serra-Sitjar M, Rodriguez J, Villalonga P, Fernandez de Mattos S. The 
tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival. 
Br  J  Haematol. 2012;156(3):334-345. 
32. Essafi M, Baudot AD, Mouska X, Cassuto JP, Ticchioni M, Deckert M. Cell-penetrating TAT -FOXO3 fusion proteins induce apoptotic cel l death in leukemic cells. Mol  Cancer   Ther. 
2011;10(1):37-46. 
33. Lain S, Xirodimas D, Lane DP. Accumulating active p53 in the nucleus by inhibition of 
nuclear export: a novel strategy to promote the p53 tumor suppressor function. Exp  Cell Res. 1999;253(2):315-324. 
34. Mutka SC, Yang WQ, Dong SD, et al. Identification of nuclear export inhibitors with potent 
anticancer activity in vivo. Cancer Res. 2009;69(2):510-517. 
35. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br  J  Cancer. 
1996;74(4):648-649. 
36. Roberts BJ, Hamelehle KL, Sebolt JS, Leopold WR. In vivo and in vitro anticancer activity 
of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Cancer Chemother  Pharmacol. 1986;16(2):95-101. 
37. Lapalombella R, Sun Q, Williams K, et al. Selective inhibitors of nuclear export show that 
CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012;120(23):4621-4634. 
38. Zhang K, Wang M, Tamayo AT, et al. Novel selective inhibitors of nucl ear export CRM1 
antagonists for therapy in mantle cell lymphoma. Exp  Hematol. 2013;41(1):67-78.e4. 
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
13 39. Shacham S, Barnard S, Kisseberth W, et al. Results of a Phase I Dose Escalation Study of the Novel, Oral CRM1 Selective Inhibitor of Nuclear Export (SIN E) KPT -335 in Dogs with 
Spontaneous Non-Hodgkin's Lymphomas (NHL). ASH Annual Meeting Abstracts. 2012;120(21):161. 
40. Lapalombella R, Zhong Y, El-Gamal D, et al. Significant in vivo efficacy of the SINE KPT-
330 in a mouse model of CLL.[abstract]. International Worshop on Chronic Lymphocytic Leukemia. 2013. 
41. Razak ARA, Soerensen MM, Mahipal A, et al. First- in-class, first -in-human phase I trial of 
KPT -330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid 
tumors. ASCO Meeting Abstracts. 2013;31(15_suppl):2505. 
42. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. 
J  Clin   Oncol. 2007;25(5):579-586. 
43 O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 
clinical trials in cancer. Biometrics. 1990 Mar;46(1):33 -48. 
 
44 Moller S. An extension of the continual reassessment methods using a preliminary up- and-
down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Statistics in medicine. 1995 May 15-30; 14(9-10):911-22; discussion 23. 
 45 Piantadosi S, Fisher JD, Grossman S. Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer chemotherapy and pharmacology. 1998; 41(6):429-36. 
 46 Garrett -Mayer, E. The continual reassessment method for dose-finding studies: a tutorial.  
Clin Trials. 2006; 3(1): 57 -71. 
    
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
14 APPENDIX A  P ERFORMANCE STATUS  CRITERIA 
 
ECOG Performance Status Scale  Karnofsky Performance Scale  
Grade  Descriptions  Percent  Description  
0 Normal activity.  Fully active, able to carry on all pre- disease 
performance without restriction.  100 Normal, no complaints, no evidence 
of disease.  
90 Able to carry on normal activity; 
minor signs or symptoms of disease.  
1 Symptoms, but ambulatory.  
Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature ( e.g., light 
housework, office work). 80 Normal activity with effort; some signs or symptoms of disease. 
70 Cares for self, unable to carry on normal activity or to do active work. 
2 In bed <50% of the time.  
Ambulatory and capable of all self-care, but unable to carry out 
any work activities.  Up and about 
more than 50% of waking hours.  60 Requires occasional assistance, but 
is able to care for most of his/her 
needs.  
50 Requires considerable assistance and 
frequent medical care.  
3 In bed >50% of the time.  Capable 
of only limited self -care, confined 
to bed or chair more than 50% of 
waking hours.  40 Disabled, requires special care and 
assistance.  
30 Severely disabled, hospitalization 
indicated.  Death not imminent.  
4 100% bedridden.  Completely 
disabled.  Cannot carry on any self-care.  Totally confined to bed 
or chair.  20 Very sick, hospitalization indicated. 
Death not imminent.  
10 Moribund, fatal processes 
progressing rapidly.  
5 Dead.  0 Dead.  
      
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
15 APPENDIX B  INDUCERS AND INHIBITORS CYP3A4/5  
 A strong inhibitor is one that causes a >5- fold increase in plasma AUC values or >80% decrease 
in clearance.  Strong inducers and inhibitors are in bold.  
 
CYP3A4/5 INDUCERS  CYP3A4/5 INHIBITORS  
  
Efavirenz Cyclosporine 
Nevirapine Indinavir 
 Miconazole 
Barbiturates Nelfinavir 
Carbamazepine Poscana zole 
Modafinil Ritonavir 
Oxcarbazepine Clarithromycin 
Phenob arbital Itracona zole 
Phen ytoin Ketocona zole 
Pioglitazone Nefazodone  
Rifabutin Saqu inavir 
Rifampin Telithromycin 
St. John's wort Voricona zole 
Troglitazone  
 Aprepitant 
 Atazanavir 
 Clotrimazole 
 Conivaptan 
 Cimetidine 
 Delavirdine 
 Desipramine 
 Diltiazem 
 Efavirenz 
 Erythromycin 
 Fluconazole 
 Fosap repitant 
 Grapefruit juice 
 Haloperidol 
 Isoniazid 
 Metronidazole 
 Nicardipine 
 Norfloxin 
 Quinidine 
 Tetracycline 
     
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
16 APPENDIX C  STAGING SYSTEMS  
  
Rai Stage – CLL Patients Only *** (Rai, 1975)  
Stage  Definition  
0 Lymphocytosis  
I Lymphocytosis  and lymphadenopathy  
II Lymphocytosis  with splenomegaly or hepatomegaly  
III Lymphocytosis with anemia (hemoglobin < 11g/dL ) 
IV Lymphocytosis with thrombocytopenia (platelets < 100,000/mm3) 
  
International Prognostic Index – NHL Patients (Except MCL)  
Patients will receive one point for each of the following 
characteristics:  
Age greater than 60 years  
Stage III or IV disease  
Elevated serum LDH  
ECOG performance status of 2, 3, or 4 
More than 1 extranodal site 
  
Mantle Cell Lymphoma International Prognostic Index – MCL Patients Only  
(Hoster, B lood 2008)  
Point(s)  Age (years)  ECOG PS  LDH  WBC (/mm3) 
0 < 50 0-1 < 0.67 x ULN  < 6,700  
1 50-59  0.67-0.99 x ULN  6,700 -9,999  
2 60-69 2-4 1.00-1.49 x ULN  10,000 -14,999  
3 ≥ 70  ≥ 1.50 x ULN  ≥ 15,000  
LDH = lactate dehydrogenase, MCL = mantle cell lymphoma, PS = performance status, ULN 
= upper limit of normal, WBC = white blood cell  
    
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
17 APPENDIX D KARYOPHARM SAE REPORT FORM  
  
OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
18  

OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
19  

OSU Protocol #:14087 
Version 7 Date:  03 August 2021 
 
20  
